0001564590-22-000782 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Nov. 30, 2021	Jan. 04, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Nov. 30, 2021
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Trading Symbol	TLRY
Entity Registrant Name	TILRAY, INC.
Entity Central Index Key	0001731348
Current Fiscal Year End Date	--05-31
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		466,522,611
Title of 12(b) Security	Class 2 Common Stock, $0.0001 par value per share
Entity File Number	001-38594
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4310622
Entity Interactive Data Current	Yes
Security Exchange Name	NASDAQ
Entity Address, Address Line One	655 Madison Avenue
Entity Address, Address Line Two	Suite 1900
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10065
City Area Code	844
Local Phone Number	845-7291
Entity Bankruptcy Proceedings, Reporting Current	true
Document Quarterly Report	true
Document Transition Report	false

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Nov. 30, 2021	May 31, 2021
Current assets
Cash and cash equivalents	$ 331,783	$ 488,466
Accounts receivable, net	84,575	87,309
Inventory	233,020	256,429
Prepaids and other current assets	57,340	48,920
Convertible notes receivable	1,560	2,485
Total current assets	708,278	883,609
Capital assets	604,249	650,698
Right-of-use assets	13,933	18,267
Intangible assets	1,450,015	1,605,918
Goodwill	2,814,163	2,832,794
Interest in equity investees	4,440	8,106
Long-term investments	168,244	17,685
Other assets	164	8,285
Total assets	5,763,486	6,025,362
Current liabilities
Bank indebtedness	8,736	8,717
Accounts payable and accrued liabilities	168,300	212,813
Contingent consideration	62,339	60,657
Warrant liability	40,455	78,168
Current portion of lease liabilities	3,588	4,264
Current portion of long-term debt	31,510	36,622
Total current liabilities	314,928	401,241
Long - term liabilities
Lease liabilities	49,265	53,946
Long-term debt	151,819	167,486
Convertible debentures	554,854	667,624
Deferred tax liability	219,311	265,845
Other liabilities	320	3,907
Total liabilities	1,290,497	1,560,049
Commitments and contingencies (refer to Note 17)
Shareholders' equity
Common stock ($0.0001 par value; 990,000,000 shares authorized; 463,802,393 and 265,423,304 shares issued and outstanding, respectively)	46	46
Additional paid-in capital	4,954,547	4,792,406
Accumulated other comprehensive income	9,595	152,668
Accumulated Deficit	(527,900)	(486,050)
Total Tilray shareholders' equity	4,436,288	4,459,070
Non-controlling interests	36,701	6,243
Total shareholders' equity	4,472,989	4,465,313
Total liabilities and shareholders' equity	$ 5,763,486	$ 6,025,362

Consolidated Statements of Financial (Parenthetical) - $ / shares	Nov. 30, 2021	May 31, 2021
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	990,000,000	990,000,000
Common stock, shares issued	463,802,393	265,423,304
Common stock, shares outstanding	463,802,393	265,423,304

Consolidated Statements of Income (Loss) and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
Income Statement [Abstract]
Net revenue	$ 155,153	$ 129,459	$ 323,176	$ 246,949
Cost of goods sold	122,387	94,176	239,455	176,721
Gross profit	32,766	35,283	83,721	70,228
Operating expenses:
General and administrative	33,469	28,273	82,956	54,245
Selling	9,210	6,079	16,642	11,896
Amortization	29,016	4,208	59,755	8,335
Marketing and promotion	7,120	4,252	12,585	9,177
Research and development	515	225	1,300	345
Transaction costs	8,120	18,206	33,699	20,664
Total operating expenses	87,450	61,243	206,937	104,662
Operating loss	(54,684)	(25,960)	(123,216)	(34,434)
Interest expense, net	(9,940)	(4,832)	(20,110)	(10,568)
Non-operating income (expense), net	64,750	(72,649)	113,610	(86,008)
Income (loss) before income taxes	126	(103,441)	(29,716)	(131,010)
Income taxes (recovery)	(5,671)	(14,192)	(909)	(20,017)
Net income (loss)	5,797	(89,249)	(28,807)	(110,993)
Total net income (loss) attributable to:
Shareholders of Tilray Inc.	(201)	(99,900)	(41,850)	(134,243)
Non-controlling interests	5,998	10,651	13,043	23,250
Other comprehensive (loss) income, net of tax
Foreign currency translation (loss) gain	(32,367)	(910)	(133,139)	475
Unrealized loss on convertible notes receivable	52		(597)
Change in fair value of long-term investments	(16,357)		(16,357)
Total other comprehensive (loss) income, net of tax	(48,672)	(910)	(150,093)	475
Comprehensive loss	(42,875)	(90,159)	(178,900)	(110,518)
Total comprehensive income (loss) attributable to:
Shareholders of Tilray Inc.	(41,853)	(100,810)	(184,923)	(133,768)
Non-controlling interests	$ (1,022)	$ 10,651	$ 6,023	$ 23,250
Weighted average number of common shares - basic	460,254,275	243,477,655	454,797,598	242,207,388
Weighted average number of common shares - diluted	460,254,275	243,477,655	454,797,598	242,207,388
Net income (loss) per share - basic	$ 0.00	$ (0.41)	$ (0.09)	$ (0.55)
Net income (loss) per share - diluted	$ 0.00	$ (0.41)	$ (0.09)	$ (0.55)

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Sweet Water	LP	Common Stock	Common Stock Sweet Water	Common Stock LP	Additional Paid-In Capital	Additional Paid-In Capital Sweet Water	Additional Paid-In Capital LP	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Non-controlling Interests	Non-controlling Interests LP
Beginning Balance at May. 31, 2020	$ 1,274,931			$ 24			$ 1,366,736			$ (5,434)	$ (113,352)	$ 26,957
Beginning Balance, Shares at May. 31, 2020				240,132,635
Share issuance - legal settlement	7,018						7,018
Share issuance - legal settlement, shares				1,389,884
Share issuance - options exercised	4						4
Share issuance - options exercised, shares				41,065
Share issuance - RSUs exercised	2,246						2,246
Share issuance - RSUs exercised, shares				429,280
Share-based payments, net	1,233						1,233
Comprehensive income (loss) for the period	(20,359)									1,385	(34,343)	12,599
Ending Balance at Aug. 31, 2020	1,265,073			$ 24			1,377,237			(4,049)	(147,695)	39,556
Ending Balance, Shares at Aug. 31, 2020				241,992,864
Beginning Balance at May. 31, 2020	1,274,931			$ 24			1,366,736			(5,434)	(113,352)	26,957
Beginning Balance, Shares at May. 31, 2020				240,132,635
Comprehensive income (loss) for the period	(110,518)
Ending Balance at Nov. 30, 2020	1,352,545			$ 27			1,554,865			(4,959)	(247,595)	50,207
Ending Balance, Shares at Nov. 30, 2020				265,423,304
Beginning Balance at Aug. 31, 2020	1,265,073			$ 24			1,377,237			(4,049)	(147,695)	39,556
Beginning Balance, Shares at Aug. 31, 2020				241,992,864
Share issuance - legal settlement	3,436						3,436
Share issuance - legal settlement, shares				503,974
Share issuance - equity financing	103,596			$ 2			103,594
Share issuance - equity financing, shares				14,610,496
Shares issued for acquisition		$ 69,190			$ 1			$ 69,189
Shares issued for acquisition, shares					8,232,810
Share issuance - options exercised	86						86
Share issuance - options exercised, shares				74,337
Share issuance - RSUs exercised	306						306
Share issuance - RSUs exercised, shares				8,823
Share-based payments, net	1,017						1,017
Comprehensive income (loss) for the period	(90,159)									(910)	(99,900)	10,651
Ending Balance at Nov. 30, 2020	1,352,545			$ 27			1,554,865			(4,959)	(247,595)	50,207
Ending Balance, Shares at Nov. 30, 2020				265,423,304
Beginning Balance at May. 31, 2021	$ 4,465,313			$ 46			4,792,406			152,668	(486,050)	6,243
Beginning Balance, Shares at May. 31, 2021	265,423,304			446,440,641
Shares issued for acquisition			$ 52,995										$ 52,995
Share issuance - options exercised	$ 2,756						2,756
Share issuance - options exercised, shares				417,489
Share issuance - RSUs exercised	6,661						6,661
Share issuance - RSUs exercised, shares				3,665,337
Share-based payments, net	(5,944)						(5,944)
Comprehensive income (loss) for the period	(136,025)									(101,421)	(41,649)	7,045
Ending Balance at Aug. 31, 2021	4,385,756			$ 46			4,795,879			51,247	(527,699)	66,283
Ending Balance, Shares at Aug. 31, 2021				450,523,467
Beginning Balance at May. 31, 2021	$ 4,465,313			$ 46			4,792,406			152,668	(486,050)	6,243
Beginning Balance, Shares at May. 31, 2021	265,423,304			446,440,641
Comprehensive income (loss) for the period	$ (178,900)
Ending Balance at Nov. 30, 2021	$ 4,472,989			$ 46			4,954,547			9,595	(527,900)	36,701
Ending Balance, Shares at Nov. 30, 2021	463,802,393			463,802,393
Beginning Balance at Aug. 31, 2021	$ 4,385,756			$ 46			4,795,879			51,247	(527,699)	66,283
Beginning Balance, Shares at Aug. 31, 2021				450,523,467
Shares issued for acquisition			$ 117,804						$ 117,804
Shares issued for acquisition, shares						9,817,061
Share issuance - DDH note							28,560					(28,560)
Share issuance - DDH note, shares				2,677,596
Share issuance - options exercised	1,939						1,939
Share issuance - options exercised, shares				98,044
Share issuance - RSUs exercised	6,314						6,314
Share issuance - RSUs exercised, shares				470,324
Share-based payments, net	4,051						4,051
Share-based payments, net, shares				215,901
Comprehensive income (loss) for the period	(42,875)									(41,652)	(201)	(1,022)
Ending Balance at Nov. 30, 2021	$ 4,472,989			$ 46			$ 4,954,547			$ 9,595	$ (527,900)	$ 36,701
Ending Balance, Shares at Nov. 30, 2021	463,802,393			463,802,393

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020
Cash used in operating activities:
Net loss	$ (28,807)	$ (110,993)
Adjustments for:
Deferred income tax recovery	(11,228)	(36,175)
Unrealized foreign exchange (gain) loss	(6,530)	6,648
Amortization	76,804	23,010
Loss on sale of capital assets	230
Inventory valuation write down	12,000
Other non-cash items	3,739	(134)
Stock-based compensation	17,670	8,339
Loss on long-term investments & equity investments	2,197	1,519
Loss (gain) on derivative instruments	(133,436)	70,342
Loss on contingent consideration	1,682
Transaction costs associated with business acquisitions		13,897
Change in non-cash working capital:
Accounts receivable	2,734	(28,570)
Prepaids and other current assets	(6,299)	(4,019)
Inventory	3,409	(18,352)
Accounts payable and accrued liabilities	(44,513)	20,827
Net cash used in operating activities	(110,348)	(53,662)
Cash used in investing activities:
Investment in capital and intangible assets	(23,856)	(29,863)
Proceeds from disposal of capital and intangible assets	8,264	6,607
Promissory notes advances		(2,419)
Repayment of notes receivable		4,032
Proceeds from disposal of long-term investments and equity investees		2,676
Net cash paid on business acquisitions		(275,603)
Net cash used in investing activities	(15,592)	(294,570)
Cash (used in) provided by financing activities:
Share capital issued, net of cash issuance costs		102,559
Proceeds (payment) from warrants and options exercised	(3,927)	90
Proceeds from long-term debt		1,881
Repayment of long-term debt	(20,779)	(2,210)
Repayment of lease liabilities	(3,360)	(71)
Increase in bank indebtedness	19	3,689
Net cash (used in) provided by financing activities	(28,047)	105,938
Effect of foreign exchange on cash and cash equivalents	(2,696)	29,853
Net decrease in cash and cash equivalents	(156,683)	(212,441)
Cash and cash equivalents, beginning of period	488,466	360,646
Cash and cash equivalents, end of period	$ 331,783	$ 148,205

Description of business

6 Months Ended

Nov. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Description of business

Note 1. Description of business

Tilray, Inc., and its wholly owned subsidiaries (collectively “Tilray”, the “Company”, “we”, or “us”) is a leading global cannabis-lifestyle and consumer packaged goods company headquartered in New York, with operations in Canada, the United States, Europe, Australia, New Zealand and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation and distribution, Tilray’s production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.

On April 30, 2021, Tilray acquired all of the issued and outstanding common shares of Aphria Inc. (“Aphria”), an international organization focused on building a global cannabis-lifestyle consumer packaged goods company in addition to its businesses in the marketing and manufacturing beverage alcohol products in the United States, and in the distribution of (non-Cannabis) pharmaceutical products in Germany and Argentina, pursuant to a plan of arrangement (the “Arrangement”) under the Business Corporations Act (Ontario).

Basis of presentation and summary of significant accounting policies

6 Months Ended

Nov. 30, 2021

Accounting Policies [Abstract]

Basis of presentation and summary of significant accounting policies

Note 2. Basis of presentation and summary of significant accounting policies

The accompanying unaudited consolidated financial statements (the “financial statements”) reflect the accounts of the Company. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The information included in this Form 10-Q should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended May 31, 2021 (the “Annual Financial Statements”). These financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The Company’s balance sheet in these interim financial statements was derived from the audited Annual Financial Statements but does not contain all of the footnote disclosures from the Annual Financial Statements.

These consolidated financial statements have been prepared on the going concern basis which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company’s accounting policies.

As a result of the April 30, 2021 business combination with Aphria, the reported results do not include the results of operations of Tilray and its subsidiaries on and prior to April 30, 2021, in accordance with the accounting treatment applicable to the Arrangement. Accordingly, comparisons between the Company's results for the three and six months ended November 30, 2021 and prior periods may not be meaningful.

Information about the accounting treatment of the Arrangement including details of the transaction, determination of the total fair value consideration, and allocation of the purchase price, are included in the Company's Annual Report for the year ended May 31, 2021 filed in Form 10-K with the U.S. Securities and Exchange Commission on July 28, 2021 (“Annual Report”).

The purchase price allocation for the Arrangement is open for adjustments and has been allocated based on estimated fair values of the assets acquired and liabilities assumed at the acquisition date. In the event that more information is obtained, the purchase price allocation may change. Any future adjustments to the purchase price allocation, including changes within identifiable intangible assets or estimation uncertainty impacted by market conditions, may impact future net earnings. The purchase price allocation adjustments can be made through the end of the measurement period, which is not to exceed one year from the acquisition date.

Basis of consolidation

Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. A complete list of our subsidiaries that existed prior to our most recent year end is included in the Company's Annual Report for the year ended May 31, 2021 filed in Form 10-K with the U.S. Securities and Exchange Commission on July 28, 2021 (“Annual Report”).

On August 13, 2021, the Company and other unrelated persons formed Superhero Acquisition L.P., a Delaware limited partnership (“SH Acquisition”), for the purpose of acquiring certain senior secured convertible notes in the principal amount of approximately $165.8 million (the “MM Notes”) originally issued by MedMen Enterprises Inc. (“MedMen”) together with certain associated warrants (the “MM Warrants”) to acquire Class B subordinate voting shares of Medmen (the “MedMen Shares”) from certain funds affiliated with Gotham Green Partners (the “MM Transaction”). The MM Notes mature on August 17, 2028. On August 17, 2021, SH Acquisition completed the MM Transaction and issued 9,817,061 shares of its common stock as partial consideration for the MM Transaction. The balance of the consideration for the MM Transaction was paid in cash by the other unrelated investors of SH Acquisition.

In connection with its issuance of 9,817,061 shares of its common stock, the Company’s received an interest in SH Acquisition equal to approximately 68% of the interests in SH Acquisition and, therefore, indirectly acquired a right to 68% of the MM Notes and related MM Warrants, which were convertible into approximately 21% of the MedMen Shares outstanding (if such MM Notes and MM Warrants were converted and exercised upon closing the MM Transaction). In addition, interest on the principal amount of the MM Notes shall accrue at an interest rate of LIBOR plus 6%, with a LIBOR floor of 2.5% and, any accrued interest shall be pay-in-kind at a price equal to the trailing 30-day volume weighted average price of the MedMen Shares, as and when such pay-in-kind interest becomes due and payable. SH Acquisition was also granted “top-up” rights enabling it (and its limited partners) to maintain its percentage ownership (on an “as-converted” basis) in the event that MedMen issues equity securities upon conversion of convertible securities that may be issued by MedMen. Tilray’s ability to convert the Notes and exercise the Warrants is dependent upon U.S. federal legalization of cannabis (a “Triggering Event”) or Tilray’s waiver of such requirement as well as any additional regulatory approvals.

Under the SH Acquisition partnership agreement, certain material events described therein require the approval of the Company, and, upon a Triggering Event, the Company has the ability to appoint two of the three members of the board of directors of the general partner of SH Acquisition. As a result, we consolidated SH Acquisition as a subsidiary of Tilray beginning on August 17, 2021. Additional information about the MM Transaction is included in Note 7 Long-term investments.

Long-term investments

Debt securities are classified as available-for-sale and are recorded at fair value and are subject to impairment testing. Other than impairment losses, unrealized gains and losses during the period, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders’ equity until realized. Upon sale, realized gain and losses are reported in net income. Debt securities are impaired when a decline in fair value is determined to be other-than-temporary. If the cost of an investment exceeds its fair value, the Company evaluates, among other factors, general market conditions, credit quality of debt instrument issuers, and the duration and extent to which the fair value is less than cost. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the statements of net loss and a new cost basis for the investment is established. The Company also evaluates whether there is a plan to sell the security or it is more likely than not that the Company will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of net loss and the remaining amount is recorded in other comprehensive income (loss).

Investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence are accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the “measurement alternative”). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments are less than carrying values. Changes in value are recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense)”.

Investments in entities over which the Company does not have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company’s share of earnings or losses reported in earnings or losses from equity method investments on the statements of net loss and comprehensive loss. Equity method investments are recorded at cost, plus the Company’s share of undistributed earnings or losses, and impairment, if any, within “Interest in equity investees” on the balance sheets. The Company assesses investments in equity method investments when events or circumstances indicate that the carrying amount of the investment may be impaired. If it is determined that the current fair value of an equity method investment is less than the carrying value of the investment, the Company will assess if the shortfall is other than temporary (OTTI). Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the equity investee to sustain an earnings capacity that would justify the carrying amount of the investment. Once a determination is made that an OTTI exists, the investment is written down to its fair value in accordance with ASC 820 at the reporting date, which establishes a new cost basis.

New accounting pronouncements not yet adopted

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which amends and simplifies existing guidance in an effort to reduce the complexity of accounting for convertible instruments and to provide financial statement users with more meaningful information. ASU 2020-06 is effective for the Company beginning June 1, 2022. This update may be applied retrospectively or on a modified retrospective basis with the cumulative effect recognized as an adjustment to the opening balance of retained earnings on the date of adoption. The Company is currently evaluating the effect of adopting this ASU.

In May 2021, the FASB issued ASU 2021-04, Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2021-04”), which amends existing guidance for earnings per share (EPS) in accordance with Topic 260. ASU 2021-04 is effective for the Company beginning June 1, 2022. This update should be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Subtopic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. ASU 2021-08 is effective for the Company beginning June 1, 2023. This update should be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.

New accounting pronouncements recently adopted

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The standard is effective for annual reporting periods beginning after December 15, 2020 and including interim periods within those fiscal years. The Company adopted the ASU beginning June 1, 2021 and the adoption of ASU 2019-12 did not have a material impact on our consolidated financial statements.

In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The Company adopted the ASU beginning June 1, 2021 and the adoption of ASU 2020-01 did not have a material impact on our consolidated financial statements.

Inventory

6 Months Ended

Nov. 30, 2021

Inventory Disclosure [Abstract]

Inventory

Note 3. Inventory

Inventory consisted of the following:

	November 30, 2021		May 31, 2021
Plants	$	19,935	$	23,083
Dried cannabis		115,970		118,269
Cannabis trim		3,725		2,931
Cannabis derivatives		28,215		24,158
Cannabis vapes		3,193		3,791
Packaging and other inventory items		22,768		31,462
Wellness inventory		12,412		15,171
Beverage alcohol inventory		4,792		5,402
Distribution inventory		22,010		32,162
Total	$	233,020	$	256,429

During the three and six months ended November 30, 2021, the Company recorded $12,000 and $12,000 in our cannabis segment of charges related to inventory write downs as a component of cost of goods sold (November 30, 2020-$0 and $0).

Capital assets

6 Months Ended

Nov. 30, 2021

Property Plant And Equipment [Abstract]

Capital assets

Note 4. Capital assets

Capital assets consisted of the following:

	November 30, 2021			May 31, 2021
Land	$	26,779		$	28,549
Production facility		411,611			346,510
Equipment		236,239			215,408
Leasehold improvement		7,444			17,059
ROU-assets under finance lease		34,798			34,726
Construction in progress		14,949			85,322
	$	731,820		$	727,574
Less: accumulated amortization		(127,571	)		(76,876	)
Total	$	604,249		$	650,698

Intangible Assets

6 Months Ended

Nov. 30, 2021

Intangible Assets Net Excluding Goodwill [Abstract]

Intangible Assets

Note 5. Intangible Assets

Intangible assets consisted of the following items:

													Intellectual
	Customer												property,
	relationships				Licenses,				Non-				trademarks,				Total
	& distribution				permits &				compete				know how				intangible
	channel				applications				agreements				& brands				assets
Cost
At May 31, 2021	$	239,810				414,930				12,453				990,917			$	1,658,110
Additions		—				182				—				856				1,038
Effect of foreign exchange		(9,300	)			(17,346	)			(659	)			(51,738	)			(79,043	)
At August 31, 2021	$	230,510				397,766				11,794				940,035			$	1,580,105
Additions		—				26				—				97				123
Effect of foreign exchange		(6,240	)			(11,776	)			—				(10,099	)			(28,115	)
At November 30, 2021	$	224,270				386,016				11,794				930,033			$	1,552,113
Accumulated amortization
At May 31, 2021	$	18,302				1,167				4,299				28,424			$	52,192
Amortization		9,466				116				833				14,684				25,099
At August 31, 2021	$	27,768				1,283				5,132				43,108			$	77,291
Amortization		10,904				122				1,188				12,593				24,807
At November 30, 2021	$	38,672				1,405				6,320				55,701			$	102,098
Net book value at May 31, 2021	$	221,508		0	$	413,763		0	$	8,154		0	$	962,493		0	$	1,605,918
Net book value at August 31, 2021	$	202,742			$	396,483			$	6,662			$	896,927			$	1,502,814
Net book value at November 30, 2021	$	185,598		0	$	384,611		0	$	5,474		0	$	874,332		0	$	1,450,015

As of November 30, 2021, included in Licenses, permits & applications is $383,445 of indefinite-lived intangible assets (May 31, 2021 - $412,000).

Expected future amortization expense for intangible assets as of November 30, 2021 are as follows:

	Amortization
2022 (remaining six months)	$	35,746
2023		63,770
2024		57,094
2025		56,091
2026		56,091
Thereafter		797,778
Total	$	1,066,570

Goodwill

6 Months Ended

Nov. 30, 2021

Goodwill Disclosure [Abstract]

Goodwill

Note 6. Goodwill

The following table shows the carrying amount of goodwill:

		November 30,		May 31,
	Segment	2021		2021
Broken Coast Cannabis Ltd.	Cannabis business	$	105,963	$	105,963
Nuuvera Corp.	Cannabis business		273,606		273,606
LATAM Holdings Inc.	Cannabis business		63,239		63,239
CC Pharma GmbH	Distribution business		4,458		4,458
SweetWater	Beverage alcohol business		100,202		100,202
Tilray-provisional	Cannabis business		2,155,471		2,144,143
Tilray-provisional	Wellness business		77,470		77,470
Effect of foreign exchange			33,754		63,713
Total		$	2,814,163	$	2,832,794

Pursuant to the Arrangement, as described in Note 1, the Company is within the measurement period of the business acquisition. As of November 30, 2021, the fair values of assets and liabilities acquired have been prepared on a provisional basis and are subject to further adjustments as the Company completes its analysis. The Company will finalize the amounts recognized by April 30, 2022. The fair value adjustments made during the three and six months ended November 30, 2021 are not significant and are reflected in the table below:

	November 30,		May 31,
	2021		2021
Assets
Cash and cash equivalents	$	375,673	$	375,673
Accounts receivable		28,054		28,054
Inventory		68,547		76,547
Prepaids and other current assets		2,960		8,960
Capital assets		136,637		136,637
Right-of-use assets, operating leases		12,606		12,606
Definite-lived intangible assets (estimated useful life)
Distribution channel (15 years)		404,000		404,000
Customer relationships (15 years)		59,000		59,000
Know how (5 years)		115,000		115,000
Brands (10 to 25 years)		301,000		301,000
Indefinite-lived intangible assets
Licenses		200,000		200,000
Goodwill-provisional		2,232,941		2,221,613
Other assets		22,879		22,879
Total assets		3,959,297		3,961,969
Liabilities
Accounts payable		62,292		62,292
Accrued expenses and other current liabilities		85,120		85,120
Accrued lease obligations		21,962		21,962
Warrant liability		79,402		79,402
Deferred tax liability		233,719		236,391
Convertible notes		267,862		267,862
Other liabilities		4,034		4,034
Total liabilities		754,391		757,063
Net assets acquired	$	3,204,906	$	3,204,906

Long-term investments

6 Months Ended

Nov. 30, 2021

Investments All Other Investments [Abstract]

Long-term investments

Note 7. Long term investments

Long term investments consisted of the following:

	November 30, 2021		May 31, 2021
Debt securities classified under available-for-sale method	$	154,442	$	—
Equity investments measured at fair value level 1		5,918		9,251
Equity investments measured at fair value level 2		2,384		2,934
Equity investments under measurement alternative		5,500		5,500
Total investments in debt and equity securities	$	168,244	$	17,685

As of November 30, 2021, the Company’s debt securities under available-for-sale method include the MM Notes, described in Note 2 Basis of presentation and summary of significant accounting policies. Interest on the principal amount of the MM Notes shall accrue at an interest rate of LIBOR plus 6%, with a LIBOR floor of 2.5% and, any accrued interest shall be pay-in-kind at a price equal to the trailing 30-day volume weighted average price of the MedMen Shares, as and when such pay-in-kind interest becomes due and payable. The MM Notes, which mature in 2028, are indirectly held by the Company through its majority-owned subsidiary, SH Acquisition. The Company has the ability, in its sole discretion, to transfer its partnership interest in SH Acquisition and/or the pro rata portion of the MM Notes and the corresponding portion of accrued and unpaid pay-in-kind interest, and/or cause the redemption of the partnership interest and/or the pro rata portion of the MM Notes held by the minority interest in SH Acquisition at any time. The total unrealized loss of $16,357 in accumulated other comprehensive income at November 30, 2021 relates to the long-term available-for-sale debt securities. The Company’s allowance for credit losses on debt securities classified as available-for-sale is $0 at November 30, 2021 and no related credit loss expenses were recorded during the three and six months ended November 30, 2021. Comparisons are not provided for the comparable prior year periods given the MM Transaction did not close until August 17, 2021.

The Company values debt securities under available-for-sale method using the Black-Scholes model (Level 3) with the following weighted-average assumptions:

Expected term	0.4 to 6.7 years
Expected volatility		70	%
Effective interest rate		20.4	%
Expected dividend yield		0.0	%
Probability of conversion	0% to 60%
Strike price	$0.15 to $4.29
Fair value of common stock	$	0.22

The Company’s equity investments at fair value consist of publicly traded shares and warrants held by the Company, including certain warrants acquired with the MM Notes and exercisable for equity securities of MedMen’s Class B subordinate voting shares. The Company’s equity investment under measurement alternative includes equity investments without readily determinable fair values.

Unrealized gains and losses recognized in non-operating income (expense) during the three and six months ended November 30, 2021 on equity investments still held at November 30, 2021 are a loss of $1,806 and a loss of $3,883 (2020 – loss of $399 and loss of $1,326). There were no impairments or adjustments to equity investments under the measurement alternative for the three and six months ended November 30, 2021 and November 30, 2020.

Accounts payable and accrued liabilities

6 Months Ended

Nov. 30, 2021

Payables And Accruals [Abstract]

Accounts payable and accrued liabilities

Note 8. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities are comprised of:

	November 30,		May 31,
	2021		2021
Trade payables	$	64,980	$	57,706
Accrued liabilities		62,915		112,594
Accrued payroll and employment related taxes		18,403		19,390
Income taxes payable		14,957		14,764
Accrued interest		6,764		148
Other accruals		281		8,211
Total	$	168,300	$	212,813

Bank indebtedness

6 Months Ended

Nov. 30, 2021

Bank Indebtedness [Abstract]

Bank indebtedness

Note 9. Bank indebtedness

The Company has an operating line of credit in the amount of C$1,000 which bears interest at the lender’s prime rate plus 75 basis points. As of November 30, 2021, the Company has not drawn on the line of credit. The operating line of credit is secured by a security interest on that certain real property at 265 Talbot St. West, Leamington, Ontario.

CC Pharma GmbH, a subsidiary of the Company, has three operating lines of credit for €8,000, €3,500, and €500 each, which bear interest at Euro Over Night Index Average plus 1.79% and Euro Interbank Offered Rate plus 3.682% respectively. As of November 30, 2021, a total of €7,353 ($8,264) was drawn down from the available credit of €12,000. The operating lines of credit are secured by a security interest in on the inventory held by CC Pharma GmbH.

Four Twenty Corporation (“420”), a subsidiary of the Company, has a revolving credit facility of $20,000 which bears interest at EURIBOR plus an applicable margin. As of November 30, 2021, the Company has not drawn any amount on the revolving line of credit. The revolving credit facility is secured by all of 420 and SweetWater’s assets and includes a corporate guarantee by a subsidiary of the Company.

Long-term debt

6 Months Ended

Nov. 30, 2021

Long Term Debt [Abstract]

Long-term debt

Note 10. Long-term debt

The following table sets forth the net carrying amount of long-term debt instruments:

	November 30,			May 31,
	2021			2021
Credit facility - C$80,000 - Canadian prime interest rate plus an applicable margin, 3-year term, with a 10-year amortization, repayable in blended monthly payments, due in November 2022	$	56,160		$	62,964
Term loan - C$25,000 - Canadian 5-year bond interest rate plus 2.73% with a minimum 4.50%, 5-year term, with a 15-year amortization, repayable in blended monthly payments, due in July 2023		13,015			14,335
Term loan - C$25,000 - 3.95%, compounded monthly, 5-year term with a 15-year amortization, repayable in equal monthly instalments of $188 including interest, due in April 2022		15,446			17,117
Term loan - C$1,250 - 3.85%, 5-year term, with a 10-year amortization, repayable in equal monthly instalments of $13 including interest, due in August 2026		505			587
Mortgage payable - C$3,750 - 3.85%, 5-year term, with a 20-year amortization, repayable in equal monthly instalments of $23 including interest, due in August 2026		2,354			2,562
Vendor take-back mortgage - C$2,850 - 6.75%, 5-year term, repayable in equal monthly instalments of $56 including interest, due in June 2021		—			92
Term loan ‐ €5,000 ‐ Euro Interbank Offered Rate plus 1.79%, 5‐year term, repayable in quarterly instalments of €250 plus interest, due in December 2023		2,543			3,356
Term loan ‐ €5,000 ‐ Euro Interbank Offered Rate plus 2.68%, 5‐year term, repayable in quarterly instalments of €250 plus interest, due in December 2023		2,543			3,356
Term loan ‐ €1,500 ‐ Euro Interbank Offered Rate plus 2.00%, 5‐year term, repayable in quarterly instalments of €98 including interest, due in April 2025		1,491			1,831
Term loan ‐ €1,500 ‐ Euro Interbank Offered Rate plus 2.00%, 5‐year term, repayable in quarterly instalments of €98 including interest, due in June 2025		1,589			1,831
Term loan - $100,000 - EUROBIR rate plus an applicable margin, 3-year term, repayable in quarterly instalments beginning March 31, 2021 of $7,500 in its first twelve months and $10,000 in each of the next two years, due in March 2024		89,375			98,138
Carrying amount of long-term debt		185,021			206,169
Unamortized financing fees		(1,692	)		(2,061	)
Net carrying amount		183,329			204,108
Less principal portion included in current liabilities		(31,510	)		(36,622	)
Total noncurrent portion of long-term debt	$	151,819		$	167,486

As of November 30, 2021, the Company was in compliance with all the long-term debt covenants.

Convertible debentures

6 Months Ended

Nov. 30, 2021

Debt Instruments [Abstract]

Convertible debentures

Note 11. Convertible debentures

The following table sets forth the net carrying amount of the convertible debentures:

	November 30,		May 31,
	2021		2021
5.25% Convertible Notes ("APHA 24")	$	284,724	$	399,444
5.00% Convertible Notes ("TLRY 23")		270,130		268,180
Total	$	554,854	$	667,624

APHA 24

	November 30,			May 31,
	2021			2021
5.25% Contractual debenture	$	350,000		$	350,000
Debt settlement		(90,760	)		(90,760	)
Fair value adjustment		25,484			140,204
Net carrying amount of APHA 24	$	284,724		$	399,444

Holders of the APHA 24 may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time between December 1, 2023 to the maturity date. The initial conversion rate for the APHA 24 will be 89.31162364 shares of common stock, par value $0.0001 per share, of Tilray, Inc. per $1,000 principal amount of Notes, which will be settled in cash, common shares of Aphria or a combination thereof, at Tilray’s election. This is equivalent to an initial conversion price of approximately $11.20 per common share, subject to adjustments in certain events. In addition, holders of the APHA 24 may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time preceding December 1, 2023, if:

(a)

the last reported sales price of the common shares for at least 20 trading days during a period of 30 consecutive trading days immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day;

(b)

during the five-business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1 principal amount of the APHA 24 for each trading day of the measurement period is less than 98% of the product of the last reported sale price of the Company’s common shares and the conversion rate on each such trading day;

(c)

the Company calls any or all of the APHA 24 for redemption or;

(d)

upon occurrence of specified corporate event.

The Company may not redeem the APHA 24 prior to June 6, 2022, except upon the occurrence of certain changes in tax laws. On or after June 6, 2022, the Company may redeem for cash all or part of the Notes, at its option, if the last reported sale price of the Company’s common shares has been at least 130% of the conversion price then in effect for at least 20 trading days during any 30 consecutive trading day period ending on and including trading day immediately preceding the date on which the Company provides notice of redemption. The redemption of the APHA 24 will be equal to 100% of the principal amount plus accrued and unpaid interest to, but excluding, the redemption date.

The Company estimated the fair value of the APHA 24 convertible debenture at November 30, 2021 at $1,098 per convertible debenture using the Black-Scholes model (Level 3) with the following weighted-average assumptions:

Risk-free interest rate		1.43	%
Expected volatility		70	%
Expected term	2.5 years
Expected dividend yield		0.0	%

Expected volatility is based on the historical volatility of the Company's common stock.

TLRY 23

	November 30,			May 31,
	2021			2021
5.00% Contractual debenture	$	277,856		$	277,856
Unamortized discount		(7,726	)		(9,676	)
Net carrying amount of TLRY 23	$	270,130		$	268,180

Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election (the “cash conversion option”). The initial conversion rate for the convertible notes is 5.9735 shares of common stock per one thousand dollar principal amount of notes, which is equivalent to an initial conversion price of approximately $167.41 per share of common stock, which represents approximately 1,659,737 shares of common stock, based on the $277,856 aggregate principal amount of convertible notes outstanding as of May 31, 2021 (2020 - $nil). Throughout the term of the TLRY 23, the conversion rate may be adjusted upon the occurrence of certain events.

Prior to the close of business on the business day immediately preceding April 1, 2023, the TLRY 23 will be convertible only under the specified circumstances. On or after April 1, 2023 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their TLRY 23, in multiples of $1 principal amount, at the option of the holder regardless of the aforementioned circumstances.

Warrant liability

6 Months Ended

Nov. 30, 2021

Warrants And Rights Note Disclosure [Abstract]

Warrant Liability

Note 12. Warrant liability

Warrants outstanding at November 30, 2021:

			Balance							Balance
	Classification	Exercise Price	May 31, 2021		Issued		Exercised/Expired			November 30, 2021
Expiration date – September 26, 2021	Equity	3.08		166,000		—		(166,000	)		—
Expiration date – January 30, 2022	Equity	9.08		5,828,651		—		—			5,828,651
Expiration date – March 17, 2025	Liability	5.95		6,209,000		—		—			6,209,000
				12,203,651		—		(166,000	)		12,037,651

	November 30, 2021					November 30, 2020
				Weighted				Weighted
	Number of			average		Number of		average
	warrants			price		warrants		price
Outstanding, opening		12,203,651		$	7.41		5,994,651	$	8.91
Exercised during the period		—			—		—		—
Issued during the period		—			—		—		—
Cancelled during the period		—			—		—		—
Expired during the period		(166,000	)	$	3.08		—		—
Outstanding, ending		12,037,651		$	7.47		5,994,651	$	8.91

The Company estimated the fair value of the Warrant liability at November 30, 2021 at $6.51 per warrant using the Black-Scholes pricing model (Level 3) with the following weighted-average assumptions:

Risk-free interest rate		1.40	%
Expected volatility		70	%
Expected term	3.80 years
Expected dividend yield		0.0	%
Strike price	$	5.95
Fair value of common stock	$	10.12

Stock-based compensation

6 Months Ended

Nov. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-based compensation

Note 13. Stock-based compensation

The Company operates stock-based compensation plans as disclosed in our Annual Report. For the three and six months ended November 30, 2021, the total stock-based compensation was $8,253 and $17,670 (2020 - $5,489 and $8,339).

During the three and six months ended November 30, 2021, the Company did not grant any further stock options or RSUs out of Aphria’s predecessor plan. The Company's total stock-based compensation expense recognized is as follows:

	For the three months ended November 30,				For the six months ended November 30,
	2021		2020		2021		2020
Stock options	$	1,939	$	879	$	4,695	$	2,250
RSUs		6,314		4,610		12,975		6,089
Total	$	8,253	$	5,489	$	17,670	$	8,339

For the three and six months ended November 30, 2021, the Company granted 69,508 and 1,414,666 performance-based RSUs, with none vesting in the period (2020 – none and none). During the three and six months ended November 30, 2021, the Company accelerated the vesting of none and 679,000 RSUs to fully vested (2020 – none and none)

Accumulated other comprehensive income (loss)

6 Months Ended

Nov. 30, 2021

Equity [Abstract]

Accumulated other comprehensive income (loss)

Note 14. Accumulated other comprehensive income (loss)

Accumulated other comprehensive loss includes the following components:

	Foreign currency translation gain (loss)			Unrealized loss on convertible notes receivables			Unrealized loss on available-for-sale debt securities			Less non-controlling interests		Total
Balance May 31, 2021	$	156,417		$	(3,749	)	$	—		$	—	$	152,668
Other comprehensive loss		(100,772	)		(649	)		—			—		(101,421	)
Balance August 31, 2021	$	55,645		$	(4,398	)	$	—		$	—	$	51,247
Other comprehensive loss		(32,367	)		52			(16,357	)		7,020		(41,652	)
Balance November 30, 2021	$	23,278		$	(4,346	)	$	(16,357	)	$	7,020	$	9,595

Non-controlling interests

6 Months Ended

Nov. 30, 2021

Text Block [Abstract]

Non-controlling interests

Note 15. Non-controlling interests

The following tables summarize the information relating to the Company’s subsidiaries, Superhero LP, CC Pharma Nordic ApS, Aphria Diamond, and ColCanna S.A.S. before intercompany eliminations. During the three and six months ended November 30, 2021, the Company made contributions to Superhero LP of $0 and $117,804 in the form of Tilray Class 2 common shares, the Company paid dividends of C$70,000 and C$70,000 (USD$56,630) to the shareholders of Aphria Diamond (“DDH note”), with the portion allocated to the non-controlling partner settled via issuance of Tilray Class 2 common shares. There were no other contributions or distributions during the period.

Non-controlling interests as of November 30, 2021:

	Superhero		CC Pharma			Aphria			ColCanna			November 30,
	LP		Nordic ApS			Diamond			S.A.S.			2021
Current assets	$	—	$	629		$	82,882		$	359		$	83,870
Non-current assets		154,442		134			156,004			141,952			452,532
Current liabilities		—		(709	)		(133,360	)		(6,639	)		(140,708	)
Non-current liabilities		—		(410	)		(62,853	)		(16	)		(63,279	)
Net assets	$	154,442	$	(356	)	$	42,673		$	135,656		$	332,415

Non-controlling interests as of May 31, 2021:

	CC Pharma			Aphria			ColCanna			May 31,
	Nordic ApS			Diamond			S.A.S.			2021
Current assets	$	919		$	19,531		$	315		$	20,765
Non-current assets		103			153,696			146,587			300,386
Current liabilities		(956	)		(28,511	)		(62	)		(29,529	)
Non-current liabilities		(406	)		(69,332	)		(6,606	)		(76,344	)
Net assets	$	(340	)	$	75,384		$	140,234		$	215,278

Non-controlling interests for the six months ended November 30, 2021:

	Superhero			CC Pharma			Aphria			ColCanna			November 30,
	LP			Nordic ApS			Diamond			S.A.S.			2021
Revenue	$	—		$	136		$	53,101		$	—		$	53,237
Total expenses		—			178			26,367			458			27,003
Net (loss) income		—			(42	)		26,734			(458	)		26,234
Other comprehensive (loss) income		(16,357	)		26			(2,817	)		(4,120	)		(23,268	)
Net comprehensive income	$	(16,357	)	$	(16	)	$	23,917		$	(4,578	)	$	2,966
Non-controlling interest %		32	%		25	%		49	%		10	%	NA
Net comprehensive (loss) income	$	(5,234	)	$	(4	)	$	11,719		$	(458	)	$	6,023

Non-controlling interests for the six months ended November 30, 2020:

	CC Pharma			Aphria			ColCanna			November 30,
	Nordic ApS			Diamond			S.A.S.			2020
Revenue	$	368		$	79,515		$	—		$	79,883
Total expenses		703			31,791			500			32,994
Net (loss) income		(335	)		47,724			(500	)		46,889
Other comprehensive (loss) income		—			—			—			—
Net comprehensive income	$	(335	)	$	47,724		$	(500	)	$	46,889
Non-controlling interest %		25	%		49	%		10	%	NA
Net comprehensive (loss) income	$	(85	)	$	23,385		$	(50	)	$	23,250

Income Taxes

6 Months Ended

Nov. 30, 2021

Income Tax Disclosure [Abstract]

Income Taxes

Note 16. Income Taxes

The determination of the Company’s overall effective tax rate requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. The effective tax rate reflects the income earned and taxed in various United States federal, state, and foreign jurisdictions. Tax law changes, increases and decreases in temporary and permanent differences between book and tax items, valuation allowances against the deferred tax assets, stock-based compensation, and the Company’s change in income in each jurisdiction all affect the overall effective tax rate. It is the Company’s practice to recognize interest and penalties related to uncertain tax positions in income tax expense.

The Company reported income tax benefit of $(5,671) and $(909) for the three and six months ended November 30, 2021 and income tax benefit of $(14,192) and $(20,017) for the three and six months ended November 30, 2020. The income tax expense (benefit) in the current period varies from the US statutory income tax rate and prior period primarily due to the geographical mix of earnings and losses with no tax benefit resulting from valuation allowances in certain jurisdictions.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Commitments and contingencies

6 Months Ended

Nov. 30, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and contingencies

Note 17. Commitments and contingencies

Purchase and other commitments

The Company has payments on long-term debt (refer to Note 10 Long-term debt), convertible notes (refer to Note 11 Convertible Debentures), material purchase commitments and construction commitments as follows:

	Total		2022 (remaining six months)		2023		2024		2025		2026		Thereafter
Long-term debt repayment	$	185,021	$	34,201	$	75,242	$	72,045	$	1,602	$	990	$	941
Convertible notes, principal and interest		599,090		13,756		27,512		298,422		259,400		—		—
Material purchase obligations		28,951		12,024		14,741		1,101		407		254		424
Construction commitments		3,534		3,534		—		—		—		—		—
Total	$	816,596	$	63,515	$	117,495	$	371,568	$	261,409	$	1,244	$	1,365

Effective November 10, 2021, the Company entered into a termination and settlement agreement with ABG Intermediate Holdings 2, LLC (“ABG”) and certain of its affiliates.  Pursuant to this settlement agreement, the Company terminated $6,600 in remaining guaranteed royalty payments owed to ABG in exchange for the payment of $3,925 as a termination fee. The termination fee was comprised of a $1,500 cash payment plus the issuance of 215,901 Class 2 common shares.

The following table presents the future undiscounted payment associated with lease liabilities as of November 30, 2021:

	Operating			Finance
	leases			leases
2022 (remaining six months)		2,071			1,114
2023		3,845			7,026
2024		3,236			2,061
2025		2,681			2,122
2026		2,898			2,186
Thereafter		7,242			39,586
Total minimum lease payments	$	21,973		$	54,095
Imputed interest		(4,240	)		(18,975	)
Obligations recognized	$	17,733		$	35,120

Legal proceedings

The Company is and may be a defendant in lawsuits from time to time in the normal course of business. While the results of litigation and claims cannot be predicted with certainty, the Company believes the reasonably possible losses of such matters, individually and in the aggregate, are not material. Additionally, the Company believes the probable final outcome of such matters will not have a material adverse effect on the Company’s consolidated results of operations, financial position, cash flows or liquidity.

Net revenue

6 Months Ended

Nov. 30, 2021

Revenues [Abstract]

Net revenue

Note 18. Net revenue

The Company reports its net revenue in four reporting segments: cannabis, distribution, beverage alcohol and wellness, in accordance with ASC 280 Segment Reporting. The Company generates revenues from these segments through contracts and purchase orders with customers, each with a single performance obligation, being the sale of products.

Net revenue is comprised of:

	For the three months ended November 30,						For the six months ended November 30,
	2021			2020			2021			2020
Cannabis revenue	$	73,429		$	70,155		$	163,362		$	137,275
Cannabis excise taxes		(14,654	)		(15,389	)		(34,138	)		(31,307	)
Net cannabis revenue		58,775			54,766			129,224			105,968
Beverage alcohol revenue		14,544			754			31,027			754
Beverage alcohol excise taxes		(837	)		(44	)		(1,859	)		(44	)
Net beverage alcohol revenue		13,707			710			29,168			710
Distribution revenue		68,869			73,983			136,055			140,271
Wellness revenue		13,802			—			28,729			—
Total	$	155,153		$	129,459		$	323,176		$	246,949

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

Cost of goods sold

6 Months Ended

Nov. 30, 2021

Cost Of Goods And Services Sold [Abstract]

Cost of goods sold

Note 19. Cost of goods sold

Cost of goods sold is comprised of:

	For the three months ended November 30,				For the six months ended November 30,
	2021		2020		2021		2020
Cannabis costs	$	45,259	$	29,632	$	85,450	$	55,407
Beverage alcohol costs		5,921		281		12,583		281
Distribution costs		61,237		64,263		120,527		121,033
Wellness costs		9,970		—		20,895		—
Total	$	122,387	$	94,176	$	239,455	$	176,721

General and administrative expenses

6 Months Ended

Nov. 30, 2021

General And Administrative Expense [Abstract]

General and administrative expenses

Note 20. General and administrative expenses

General and administrative expenses are comprised of:

	For the three months ended November 30,				For the six months ended November 30,
	2021		2020		2021		2020
Executive compensation	$	2,237	$	2,711	$	5,327	$	4,961
Office and general		5,206		4,418		17,973		8,839
Salaries and wages		8,149		8,821		23,460		18,164
Stock-based compensation		8,253		5,489		17,670		8,339
Insurance		4,995		2,904		9,626		6,110
Professional fees		3,355		3,171		6,068		6,106
Travel and accommodation		982		525		1,774		1,252
Rent		292		234		1,058		474
Total	$	33,469	$	28,273	$	82,956	$	54,245

Non-operating income (expense)

6 Months Ended

Nov. 30, 2021

Nonoperating Income Expense [Abstract]

Non-operating income (expense)

Note 21. Non-operating income (expense)

Non-operating income (expense) is comprised of:

	For the three months ended November 30,						For the six months ended November 30,
	2021			2020			2021			2020
Change in fair value of convertible debenture	$	56,353		$	(70,683	)	$	95,723		$	(70,343	)
Change in fair value of warrant liability		20,178			—			37,713			—
Foreign exchange loss		(10,180	)		(3,371	)		(15,904	)		(19,702	)
Loss on long-term investments		(1,833	)		(399	)		(3,508	)		(1,519	)
Gain from equity investees		—			—			1,356			—
Other non-operating (losses) gains, net		232			1,804			(1,770	)		5,556
Total	$	64,750		$	(72,649	)	$	113,610		$	(86,008	)

Fair Value Measurements

6 Months Ended

Nov. 30, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 22.

Fair value measurements

Financial instruments

The Company has classified its financial instruments as described in Note 3 Significant accounting policies in our Annual Report.

The carrying values of accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity.

At November 30, 2021 the Company’s long-term debt of $18,305 (May 31, 2021 - $20,358) is subject to fixed interest rates. The Company’s long-term debt is valued based on discounting the future cash outflows associated with the long-term debt. The discount rate is based on the incremental premium above market rates for Government of Canada securities of similar duration. In each period thereafter, the incremental premium is held constant while the Government of Canada security is based on the then current market value to derive the discount rate.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of November 30, 2021 and May 31, 2021 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

							November 30,
	Level 1		Level 2		Level 3		2021
Financial assets
Cash and cash equivalents	$	331,783	$	—	$	—	$	331,783
Convertible notes receivable		—		1,560		—		1,560
Equity investments measured at fair value		5,918		2,384		—		8,302
Debt securities classified under available-for-sale method		—		—		154,442		154,442
Financial liabilities
Warrant liability		—		—		40,455		40,455
Contingent consideration		—		—		62,339		62,339
APHA 24 Convertible debenture		—		—		284,724		284,724
Total recurring fair value measurements	$	337,701	$	3,944	$	541,960	$	883,605

							May 31,
	Level 1		Level 2		Level 3		2021
Financial assets
Cash and cash equivalents	$	488,466	—		—		$	488,466
Convertible notes receivable	—			2,485	—			2,485
Equity investments measured at fair value		9,251		2,934	—			12,185
Debt securities classified under available-for-sale method	—			—	—			—
Financial liabilities
Warrant liability	—		—			78,168		78,168
Contingent consideration	—		—			60,657		60,657
APHA 24 Convertible debenture	—		—			399,444		399,444
Total recurring fair value measurements	$	497,717	$	5,419	$	538,269	$	1,041,405

The Company’s financial assets and liabilities required to be measured on a recurring basis are its equity investments measured at fair value, debt securities classified as available-for-sale, acquisition-related contingent consideration, and warrant liability.

Convertible notes receivable, and equity investments recorded at fair value. The estimated fair value is determined using quoted market prices, broker or dealer quotations or discounted cash flows and is classified as Level 2. Certain equity investments recorded at fair value have quoted prices in active markets for identical assets and are classified as Level 1.

Debt securities classified as available-for sale are recorded at fair value. The estimated fair value is determined using the Black-Scholes option pricing model and is classified as Level 3. The Company classified these securities as level 2 in the period of acquisition, when the valuation was determined to reflect the recent market transaction.

The warrants associated with the warrant liability are classified as Level 3 derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Black-Scholes pricing model. Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity, the warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period with the change in fair value recorded in change in fair value of warrant liability. Any significant adjustments to the unobservable inputs disclosed in the table below would have a direct impact on the fair value of the warrant liability.

The contingent consideration from the acquisition of SweetWater, first due in December 2023 and payable in cash, is determined by discounting future expected cash outflows at a discount rate of 5%. The inputs into the future expected cash outflows are classified as Level 3.

The APHA 24 Convertible debentures are recorded at fair value. The estimated fair value is determined using the Black-Scholes option pricing model and is classified as Level 3.

The balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows:

	APHA 24									Debt
	Convertible			Warrant			Contingent			Securities
	Debt			Liability			Consideration			AFS			Total
Balance, May 31, 2021		(399,444	)		(78,168	)		(60,657	)		—			(538,269	)
Additions		—			—			—			170,799			170,799
Disposals		—			—			—			—			—
Unrealized gain (loss) on fair value		114,720			37,713			(1,682	)		(16,357	)		134,394
Balance, November 30, 2021	$	(284,724	)	$	(40,455	)	$	(62,339	)	$	154,442		$	(233,076	)

The unrealized gain (loss) on fair value for the convertible debenture, the warrant liability, contingent consideration, and debt securities classified under available-for-sale method is recognized in non-operating income (loss) using the following inputs:

Financial asset / financial liability	Valuation technique	Significant unobservable input	Inputs
APHA Convertible debentures	Black-Scholes	Volatility, expected life	70% 2.5 years
Warrant liability	Black-Scholes	Volatility, expected life	70% 3.8 years
Contingent consideration	Discounted cash flows	Discount rate, achievement	5% 100%
Debt securities classified under available-for-sale method	Black-Scholes	Interest rate, conversion	20% 0% to 60%

Items measured at fair value on a non-recurring basis

The Company's prepaids and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company’s capital management approach in the period. The Company considers its cash and cash equivalents and marketable securities as capital.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Segment reporting

6 Months Ended

Nov. 30, 2021

Segment Reporting [Abstract]

Segment reporting

Note 23.

Segment reporting

The Company operates in four reporting segments. 1) cannabis operations, which encompasses the production, distribution and sale of both medical and adult-use cannabis, 2) beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products, 3) distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers, and 4) wellness products, which encompasses hemp foods and cannabidiol (“CBD”) products. This structure is in line with how our Chief Operating Decision Maker (“CODM”) assesses our performance and allocates resources.

Operating segments have not been aggregated and no asset information is provided for the segments because the Company’s CODM does not receive asset information by segment on a regular basis. While the Company reported “business under development” as a fifth segment in its previous Annual Report, management determined that this no longer met the definition of a reporting segment.

Segment net revenue from external customers:

	For the three months ended November 30,				For the six months ended November 30,
		2021		2020		2021		2020
Cannabis business	$	58,775	$	54,766	$	129,224	$	105,968
Distribution business		68,869		73,983		136,055		140,271
Beverage alcohol business		13,707		710		29,168		710
Wellness business		13,802		—		28,729		—
Total	$	155,153	$	129,459	$	323,176	$	246,949

Segment gross profit from external customers:

	For the three months ended November 30,				For the six months ended November 30,
	2021		2020		2021		2020
Cannabis business	$	13,516	$	25,134	$	43,774	$	50,561
Distribution business		7,632		9,720		15,528		19,238
Beverage alcohol business		7,786		429		16,585		429
Wellness business		3,832		—		7,834		—
Total	$	32,766	$	35,283	$	83,721	$	70,228

Channels of Cannabis revenue were as follows:

	For the three months ended November 30,						For the six months ended November 30,
	2021			2020			2021			2020
Revenue from Canadian medical cannabis products	$	7,929		$	6,260		$	16,303		$	12,640
Revenue from Canadian adult-use cannabis products		49,535			58,175			119,128			115,123
Revenue from wholesale cannabis products		2,259			1,440			3,959			5,232
Revenue from international cannabis products		13,706			4,280			23,972			4,280
Less excise taxes		(14,654	)		(15,389	)		(34,138	)		(31,307	)
Total	$	58,775		$	54,766		$	129,224		$	105,968

Geographic net revenue:

	For the three months ended November 30,				For the six months ended November 30,
	2021		2020		2021		2020
North America	$	72,443	$	54,475	$	162,986	$	105,667
EMEA		74,916		73,714		150,925		138,791
Rest of World		7,794		1,270		9,265		2,491
Total	$	155,153	$	129,459	$	323,176	$	246,949

Geographic capital assets:

	November 30, 2021		May 31, 2021
North America	$	467,646	$	504,575
EMEA		132,666		140,838
Rest of World		3,937		5,285
Total	$	604,249	$	650,698

Major customers are defined as customers that each individually account for greater than 10% of the Company’s annual revenues. For the three and six months ended November 30, 2021 and 2020, there were no major customers representing greater than 10% of our annual revenues.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Subsequent Events

6 Months Ended

Nov. 30, 2021

Subsequent Events [Abstract]

Subsequent Events

Note 24.

Subsequent Events

On December 1, 2021, the Company acquired all the membership interests in Cheese Grits, LLC, a Georgia limited liability company that owns the SweetWater Brewing Company brewery and taproom in Atlanta, Georgia (the “SW Acquisition”), which facility was previously leased to the Company. As consideration for the SW Acquisition, the Company paid a purchase price at closing equal to $30,665, which purchase price was satisfied through the assumption of outstanding debt as well as the issuance of 843,687 shares of Tilray’s Class 2 common stock with a fair value of $8,741. On December 17, 2021, the Company issued an additional 82,224 Class 2 common shares with a fair value at issuance of $776 to satisfy its contractual obligations under the SW Acquisition.

On December 7, 2021, the Company acquired all the membership interests in of Double Diamond Distillery LLC (d/b/a Breckenridge Distillery), a Colorado limited liability company and a leading distilled spirits brand located in Breckenridge, Colorado, widely known for its award-winning bourbon whiskey collection and innovative craft spirits portfolio (the “Breckenridge Acquisition”). As consideration for the Breckenridge Acquisition, the Company paid a purchase price in an aggregate amount equal to $102,900, which purchase price was satisfied through the issuance of 11,245,511 shares of Tilray’s Class 2 common shares.

On December 7, 2021, the Company entered into the Second Amendment to Credit Agreement (the “Amendment”) with the Bank of Montreal (as amended, the “Credit Agreement”). The Amendment reduced our total outstanding long-term debt under the Credit Agreement to $79,375 and increased our current line of credit to $30,000. On December 7, 2021, the Company drew $10,000 borrowed on the line of credit.

On December 17, 2021, the Company acquired certain assets from WC IPA LLC, consisting of certain intellectual property, inventory and other assets relating to the Alpine and Green Flash brands (the “Alpine Acquisition”). As consideration for the Alpine Acquisition, the Company paid a purchase price in an aggregate amount equal to $5,133, which purchase price was satisfied through the payment of cash and the issuance of 366,308 shares of Tilray’s Class 2 common shares with a fair value of $3,000.

Basis of presentation and summary of significant accounting policies (Policies)	6 Months Ended
	Nov. 30, 2021
Accounting Policies [Abstract]
Basis of consolidation	Basis of consolidation Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. A complete list of our subsidiaries that existed prior to our most recent year end is included in the Company's Annual Report for the year ended May 31, 2021 filed in Form 10-K with the U.S. Securities and Exchange Commission on July 28, 2021 (“Annual Report”). On August 13, 2021, the Company and other unrelated persons formed Superhero Acquisition L.P., a Delaware limited partnership (“SH Acquisition”), for the purpose of acquiring certain senior secured convertible notes in the principal amount of approximately $165.8 million (the “MM Notes”) originally issued by MedMen Enterprises Inc. (“MedMen”) together with certain associated warrants (the “MM Warrants”) to acquire Class B subordinate voting shares of Medmen (the “MedMen Shares”) from certain funds affiliated with Gotham Green Partners (the “MM Transaction”). The MM Notes mature on August 17, 2028. On August 17, 2021, SH Acquisition completed the MM Transaction and issued 9,817,061 shares of its common stock as partial consideration for the MM Transaction. The balance of the consideration for the MM Transaction was paid in cash by the other unrelated investors of SH Acquisition. In connection with its issuance of 9,817,061 shares of its common stock, the Company’s received an interest in SH Acquisition equal to approximately 68% of the interests in SH Acquisition and, therefore, indirectly acquired a right to 68% of the MM Notes and related MM Warrants, which were convertible into approximately 21% of the MedMen Shares outstanding (if such MM Notes and MM Warrants were converted and exercised upon closing the MM Transaction). In addition, interest on the principal amount of the MM Notes shall accrue at an interest rate of LIBOR plus 6%, with a LIBOR floor of 2.5% and, any accrued interest shall be pay-in-kind at a price equal to the trailing 30-day volume weighted average price of the MedMen Shares, as and when such pay-in-kind interest becomes due and payable. SH Acquisition was also granted “top-up” rights enabling it (and its limited partners) to maintain its percentage ownership (on an “as-converted” basis) in the event that MedMen issues equity securities upon conversion of convertible securities that may be issued by MedMen. Tilray’s ability to convert the Notes and exercise the Warrants is dependent upon U.S. federal legalization of cannabis (a “Triggering Event”) or Tilray’s waiver of such requirement as well as any additional regulatory approvals. Under the SH Acquisition partnership agreement, certain material events described therein require the approval of the Company, and, upon a Triggering Event, the Company has the ability to appoint two of the three members of the board of directors of the general partner of SH Acquisition. As a result, we consolidated SH Acquisition as a subsidiary of Tilray beginning on August 17, 2021. Additional information about the MM Transaction is included in Note 7 Long-term investments.
Long-term investments	Long-term investments Debt securities are classified as available-for-sale and are recorded at fair value and are subject to impairment testing. Other than impairment losses, unrealized gains and losses during the period, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders’ equity until realized. Upon sale, realized gain and losses are reported in net income. Debt securities are impaired when a decline in fair value is determined to be other-than-temporary. If the cost of an investment exceeds its fair value, the Company evaluates, among other factors, general market conditions, credit quality of debt instrument issuers, and the duration and extent to which the fair value is less than cost. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the statements of net loss and a new cost basis for the investment is established. The Company also evaluates whether there is a plan to sell the security or it is more likely than not that the Company will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of net loss and the remaining amount is recorded in other comprehensive income (loss). Investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence are accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the “measurement alternative”). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments are less than carrying values. Changes in value are recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense)”. Investments in entities over which the Company does not have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company’s share of earnings or losses reported in earnings or losses from equity method investments on the statements of net loss and comprehensive loss. Equity method investments are recorded at cost, plus the Company’s share of undistributed earnings or losses, and impairment, if any, within “Interest in equity investees” on the balance sheets. The Company assesses investments in equity method investments when events or circumstances indicate that the carrying amount of the investment may be impaired. If it is determined that the current fair value of an equity method investment is less than the carrying value of the investment, the Company will assess if the shortfall is other than temporary (OTTI). Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the equity investee to sustain an earnings capacity that would justify the carrying amount of the investment. Once a determination is made that an OTTI exists, the investment is written down to its fair value in accordance with ASC 820 at the reporting date, which establishes a new cost basis.
New accounting pronouncements recently adopted/ not yet adopted	New accounting pronouncements not yet adopted In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which amends and simplifies existing guidance in an effort to reduce the complexity of accounting for convertible instruments and to provide financial statement users with more meaningful information. ASU 2020-06 is effective for the Company beginning June 1, 2022. This update may be applied retrospectively or on a modified retrospective basis with the cumulative effect recognized as an adjustment to the opening balance of retained earnings on the date of adoption. The Company is currently evaluating the effect of adopting this ASU. In May 2021, the FASB issued ASU 2021-04, Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2021-04”), which amends existing guidance for earnings per share (EPS) in accordance with Topic 260. ASU 2021-04 is effective for the Company beginning June 1, 2022. This update should be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU. In October 2021, the FASB issued ASU 2021-08, Business Combinations (Subtopic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. ASU 2021-08 is effective for the Company beginning June 1, 2023. This update should be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU. New accounting pronouncements recently adopted In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The standard is effective for annual reporting periods beginning after December 15, 2020 and including interim periods within those fiscal years. The Company adopted the ASU beginning June 1, 2021 and the adoption of ASU 2019-12 did not have a material impact on our consolidated financial statements. In January 2020, the FASB issued ASU 2020-01, Investments – Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The Company adopted the ASU beginning June 1, 2021 and the adoption of ASU 2020-01 did not have a material impact on our consolidated financial statements.

Inventory (Tables)

6 Months Ended

Nov. 30, 2021

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory consisted of the following:

	November 30, 2021		May 31, 2021
Plants	$	19,935	$	23,083
Dried cannabis		115,970		118,269
Cannabis trim		3,725		2,931
Cannabis derivatives		28,215		24,158
Cannabis vapes		3,193		3,791
Packaging and other inventory items		22,768		31,462
Wellness inventory		12,412		15,171
Beverage alcohol inventory		4,792		5,402
Distribution inventory		22,010		32,162
Total	$	233,020	$	256,429

Capital assets (Tables)

6 Months Ended

Nov. 30, 2021

Property Plant And Equipment [Abstract]

Summary of Capital Assets

Capital assets consisted of the following:

	November 30, 2021			May 31, 2021
Land	$	26,779		$	28,549
Production facility		411,611			346,510
Equipment		236,239			215,408
Leasehold improvement		7,444			17,059
ROU-assets under finance lease		34,798			34,726
Construction in progress		14,949			85,322
	$	731,820		$	727,574
Less: accumulated amortization		(127,571	)		(76,876	)
Total	$	604,249		$	650,698

Intangible Assets (Tables)

6 Months Ended

Nov. 30, 2021

Intangible Assets Net Excluding Goodwill [Abstract]

Schedule of Intangible Assets

Intangible assets consisted of the following items:

													Intellectual
	Customer												property,
	relationships				Licenses,				Non-				trademarks,				Total
	& distribution				permits &				compete				know how				intangible
	channel				applications				agreements				& brands				assets
Cost
At May 31, 2021	$	239,810				414,930				12,453				990,917			$	1,658,110
Additions		—				182				—				856				1,038
Effect of foreign exchange		(9,300	)			(17,346	)			(659	)			(51,738	)			(79,043	)
At August 31, 2021	$	230,510				397,766				11,794				940,035			$	1,580,105
Additions		—				26				—				97				123
Effect of foreign exchange		(6,240	)			(11,776	)			—				(10,099	)			(28,115	)
At November 30, 2021	$	224,270				386,016				11,794				930,033			$	1,552,113
Accumulated amortization
At May 31, 2021	$	18,302				1,167				4,299				28,424			$	52,192
Amortization		9,466				116				833				14,684				25,099
At August 31, 2021	$	27,768				1,283				5,132				43,108			$	77,291
Amortization		10,904				122				1,188				12,593				24,807
At November 30, 2021	$	38,672				1,405				6,320				55,701			$	102,098
Net book value at May 31, 2021	$	221,508		0	$	413,763		0	$	8,154		0	$	962,493		0	$	1,605,918
Net book value at August 31, 2021	$	202,742			$	396,483			$	6,662			$	896,927			$	1,502,814
Net book value at November 30, 2021	$	185,598		0	$	384,611		0	$	5,474		0	$	874,332		0	$	1,450,015

Schedule of Estimated Amortization Expense

Expected future amortization expense for intangible assets as of November 30, 2021 are as follows:

	Amortization
2022 (remaining six months)	$	35,746
2023		63,770
2024		57,094
2025		56,091
2026		56,091
Thereafter		797,778
Total	$	1,066,570

Goodwill (Tables)

6 Months Ended

Nov. 30, 2021

Goodwill [Line Items]

Schedule of Carrying Amount of Goodwill

The following table shows the carrying amount of goodwill:

		November 30,		May 31,
	Segment	2021		2021
Broken Coast Cannabis Ltd.	Cannabis business	$	105,963	$	105,963
Nuuvera Corp.	Cannabis business		273,606		273,606
LATAM Holdings Inc.	Cannabis business		63,239		63,239
CC Pharma GmbH	Distribution business		4,458		4,458
SweetWater	Beverage alcohol business		100,202		100,202
Tilray-provisional	Cannabis business		2,155,471		2,144,143
Tilray-provisional	Wellness business		77,470		77,470
Effect of foreign exchange			33,754		63,713
Total		$	2,814,163	$	2,832,794

Aphria Inc

Goodwill [Line Items]

Summary of Fair Values of Assets Acquired and Liabilities Assumed

The fair value adjustments made during the three and six months ended November 30, 2021 are not significant and are reflected in the table below:

	November 30,		May 31,
	2021		2021
Assets
Cash and cash equivalents	$	375,673	$	375,673
Accounts receivable		28,054		28,054
Inventory		68,547		76,547
Prepaids and other current assets		2,960		8,960
Capital assets		136,637		136,637
Right-of-use assets, operating leases		12,606		12,606
Definite-lived intangible assets (estimated useful life)
Distribution channel (15 years)		404,000		404,000
Customer relationships (15 years)		59,000		59,000
Know how (5 years)		115,000		115,000
Brands (10 to 25 years)		301,000		301,000
Indefinite-lived intangible assets
Licenses		200,000		200,000
Goodwill-provisional		2,232,941		2,221,613
Other assets		22,879		22,879
Total assets		3,959,297		3,961,969
Liabilities
Accounts payable		62,292		62,292
Accrued expenses and other current liabilities		85,120		85,120
Accrued lease obligations		21,962		21,962
Warrant liability		79,402		79,402
Deferred tax liability		233,719		236,391
Convertible notes		267,862		267,862
Other liabilities		4,034		4,034
Total liabilities		754,391		757,063
Net assets acquired	$	3,204,906	$	3,204,906

Long-term investments (Tables)

6 Months Ended

Nov. 30, 2021

Schedule of Long-term Investments

Long term investments consisted of the following:

	November 30, 2021		May 31, 2021
Debt securities classified under available-for-sale method	$	154,442	$	—
Equity investments measured at fair value level 1		5,918		9,251
Equity investments measured at fair value level 2		2,384		2,934
Equity investments under measurement alternative		5,500		5,500
Total investments in debt and equity securities	$	168,244	$	17,685

Schedule of Estimated Fair Value of Convertible Debenture / Warrant Liability, Contingent Consideration and Debt Securities Classified under Available-for-sale Method

Risk-free interest rate		1.40	%
Expected volatility		70	%
Expected term	3.80 years
Expected dividend yield		0.0	%
Strike price	$	5.95
Fair value of common stock	$	10.12

Financial asset / financial liability	Valuation technique	Significant unobservable input	Inputs
APHA Convertible debentures	Black-Scholes	Volatility, expected life	70% 2.5 years
Warrant liability	Black-Scholes	Volatility, expected life	70% 3.8 years
Contingent consideration	Discounted cash flows	Discount rate, achievement	5% 100%
Debt securities classified under available-for-sale method	Black-Scholes	Interest rate, conversion	20% 0% to 60%

Available-for-sale Securities [Member]

Schedule of Estimated Fair Value of Convertible Debenture / Warrant Liability, Contingent Consideration and Debt Securities Classified under Available-for-sale Method

The Company values debt securities under available-for-sale method using the Black-Scholes model (Level 3) with the following weighted-average assumptions:

Expected term	0.4 to 6.7 years
Expected volatility		70	%
Effective interest rate		20.4	%
Expected dividend yield		0.0	%
Probability of conversion	0% to 60%
Strike price	$0.15 to $4.29
Fair value of common stock	$	0.22

Accounts payable and accrued liabilities (Tables)

6 Months Ended

Nov. 30, 2021

Payables And Accruals [Abstract]

Summary of Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities are comprised of:

	November 30,		May 31,
	2021		2021
Trade payables	$	64,980	$	57,706
Accrued liabilities		62,915		112,594
Accrued payroll and employment related taxes		18,403		19,390
Income taxes payable		14,957		14,764
Accrued interest		6,764		148
Other accruals		281		8,211
Total	$	168,300	$	212,813

Long-term debt (Tables)

6 Months Ended

Nov. 30, 2021

Long Term Debt [Abstract]

Schedule of Net Carrying Amount of Long-term Debt Instruments

The following table sets forth the net carrying amount of long-term debt instruments:

	November 30,			May 31,
	2021			2021
Credit facility - C$80,000 - Canadian prime interest rate plus an applicable margin, 3-year term, with a 10-year amortization, repayable in blended monthly payments, due in November 2022	$	56,160		$	62,964
Term loan - C$25,000 - Canadian 5-year bond interest rate plus 2.73% with a minimum 4.50%, 5-year term, with a 15-year amortization, repayable in blended monthly payments, due in July 2023		13,015			14,335
Term loan - C$25,000 - 3.95%, compounded monthly, 5-year term with a 15-year amortization, repayable in equal monthly instalments of $188 including interest, due in April 2022		15,446			17,117
Term loan - C$1,250 - 3.85%, 5-year term, with a 10-year amortization, repayable in equal monthly instalments of $13 including interest, due in August 2026		505			587
Mortgage payable - C$3,750 - 3.85%, 5-year term, with a 20-year amortization, repayable in equal monthly instalments of $23 including interest, due in August 2026		2,354			2,562
Vendor take-back mortgage - C$2,850 - 6.75%, 5-year term, repayable in equal monthly instalments of $56 including interest, due in June 2021		—			92
Term loan ‐ €5,000 ‐ Euro Interbank Offered Rate plus 1.79%, 5‐year term, repayable in quarterly instalments of €250 plus interest, due in December 2023		2,543			3,356
Term loan ‐ €5,000 ‐ Euro Interbank Offered Rate plus 2.68%, 5‐year term, repayable in quarterly instalments of €250 plus interest, due in December 2023		2,543			3,356
Term loan ‐ €1,500 ‐ Euro Interbank Offered Rate plus 2.00%, 5‐year term, repayable in quarterly instalments of €98 including interest, due in April 2025		1,491			1,831
Term loan ‐ €1,500 ‐ Euro Interbank Offered Rate plus 2.00%, 5‐year term, repayable in quarterly instalments of €98 including interest, due in June 2025		1,589			1,831
Term loan - $100,000 - EUROBIR rate plus an applicable margin, 3-year term, repayable in quarterly instalments beginning March 31, 2021 of $7,500 in its first twelve months and $10,000 in each of the next two years, due in March 2024		89,375			98,138
Carrying amount of long-term debt		185,021			206,169
Unamortized financing fees		(1,692	)		(2,061	)
Net carrying amount		183,329			204,108
Less principal portion included in current liabilities		(31,510	)		(36,622	)
Total noncurrent portion of long-term debt	$	151,819		$	167,486

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69B
-URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 55
-Paragraph 69E
-URI http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644

+ Details

Convertible debentures (Tables)

6 Months Ended

Nov. 30, 2021

Debt Instrument [Line Items]

Schedule of Estimated Fair Value of Convertible Debenture / Warrant Liability, Contingent Consideration and Debt Securities Classified under Available-for-sale Method

Risk-free interest rate		1.40	%
Expected volatility		70	%
Expected term	3.80 years
Expected dividend yield		0.0	%
Strike price	$	5.95
Fair value of common stock	$	10.12

Financial asset / financial liability	Valuation technique	Significant unobservable input	Inputs
APHA Convertible debentures	Black-Scholes	Volatility, expected life	70% 2.5 years
Warrant liability	Black-Scholes	Volatility, expected life	70% 3.8 years
Contingent consideration	Discounted cash flows	Discount rate, achievement	5% 100%
Debt securities classified under available-for-sale method	Black-Scholes	Interest rate, conversion	20% 0% to 60%

Convertible Debentures

Debt Instrument [Line Items]

Summary of Convertible Notes Receivable

The following table sets forth the net carrying amount of the convertible debentures:

	November 30,		May 31,
	2021		2021
5.25% Convertible Notes ("APHA 24")	$	284,724	$	399,444
5.00% Convertible Notes ("TLRY 23")		270,130		268,180
Total	$	554,854	$	667,624

APHA 24

Debt Instrument [Line Items]

Summary of Convertible Notes Receivable

APHA 24

	November 30,			May 31,
	2021			2021
5.25% Contractual debenture	$	350,000		$	350,000
Debt settlement		(90,760	)		(90,760	)
Fair value adjustment		25,484			140,204
Net carrying amount of APHA 24	$	284,724		$	399,444

Schedule of Estimated Fair Value of Convertible Debenture / Warrant Liability, Contingent Consideration and Debt Securities Classified under Available-for-sale Method

Risk-free interest rate		1.43	%
Expected volatility		70	%
Expected term	2.5 years
Expected dividend yield		0.0	%

TLRY 23

Debt Instrument [Line Items]

Summary of Convertible Notes Receivable

TLRY 23

	November 30,			May 31,
	2021			2021
5.00% Contractual debenture	$	277,856		$	277,856
Unamortized discount		(7,726	)		(9,676	)
Net carrying amount of TLRY 23	$	270,130		$	268,180

Warrant Liability (Tables)

6 Months Ended

Nov. 30, 2021

Warrants And Rights Note Disclosure [Abstract]

Schedule of Warrants Outstanding

Warrants outstanding at November 30, 2021:

			Balance							Balance
	Classification	Exercise Price	May 31, 2021		Issued		Exercised/Expired			November 30, 2021
Expiration date – September 26, 2021	Equity	3.08		166,000		—		(166,000	)		—
Expiration date – January 30, 2022	Equity	9.08		5,828,651		—		—			5,828,651
Expiration date – March 17, 2025	Liability	5.95		6,209,000		—		—			6,209,000
				12,203,651		—		(166,000	)		12,037,651

	November 30, 2021					November 30, 2020
				Weighted				Weighted
	Number of			average		Number of		average
	warrants			price		warrants		price
Outstanding, opening		12,203,651		$	7.41		5,994,651	$	8.91
Exercised during the period		—			—		—		—
Issued during the period		—			—		—		—
Cancelled during the period		—			—		—		—
Expired during the period		(166,000	)	$	3.08		—		—
Outstanding, ending		12,037,651		$	7.47		5,994,651	$	8.91

Schedule of Estimated Fair Value of Convertible Debenture / Warrant Liability, Contingent Consideration and Debt Securities Classified under Available-for-sale Method

Risk-free interest rate		1.40	%
Expected volatility		70	%
Expected term	3.80 years
Expected dividend yield		0.0	%
Strike price	$	5.95
Fair value of common stock	$	10.12

Financial asset / financial liability	Valuation technique	Significant unobservable input	Inputs
APHA Convertible debentures	Black-Scholes	Volatility, expected life	70% 2.5 years
Warrant liability	Black-Scholes	Volatility, expected life	70% 3.8 years
Contingent consideration	Discounted cash flows	Discount rate, achievement	5% 100%
Debt securities classified under available-for-sale method	Black-Scholes	Interest rate, conversion	20% 0% to 60%

Stock-based compensation (Tables)

6 Months Ended

Nov. 30, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Based Compensation Recognized

The Company's total stock-based compensation expense recognized

	For the three months ended November 30,				For the six months ended November 30,
	2021		2020		2021		2020
Stock options	$	1,939	$	879	$	4,695	$	2,250
RSUs		6,314		4,610		12,975		6,089
Total	$	8,253	$	5,489	$	17,670	$	8,339

Accumulated other comprehensive income (loss) (Tables)

6 Months Ended

Nov. 30, 2021

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss includes the following components:

	Foreign currency translation gain (loss)			Unrealized loss on convertible notes receivables			Unrealized loss on available-for-sale debt securities			Less non-controlling interests		Total
Balance May 31, 2021	$	156,417		$	(3,749	)	$	—		$	—	$	152,668
Other comprehensive loss		(100,772	)		(649	)		—			—		(101,421	)
Balance August 31, 2021	$	55,645		$	(4,398	)	$	—		$	—	$	51,247
Other comprehensive loss		(32,367	)		52			(16,357	)		7,020		(41,652	)
Balance November 30, 2021	$	23,278		$	(4,346	)	$	(16,357	)	$	7,020	$	9,595

Non-controlling interests (Tables)

6 Months Ended

Nov. 30, 2021

Text Block [Abstract]

Summary of Information Relating to Company's Subsidiaries

Non-controlling interests as of November 30, 2021:

	Superhero		CC Pharma			Aphria			ColCanna			November 30,
	LP		Nordic ApS			Diamond			S.A.S.			2021
Current assets	$	—	$	629		$	82,882		$	359		$	83,870
Non-current assets		154,442		134			156,004			141,952			452,532
Current liabilities		—		(709	)		(133,360	)		(6,639	)		(140,708	)
Non-current liabilities		—		(410	)		(62,853	)		(16	)		(63,279	)
Net assets	$	154,442	$	(356	)	$	42,673		$	135,656		$	332,415

Non-controlling interests as of May 31, 2021:

	CC Pharma			Aphria			ColCanna			May 31,
	Nordic ApS			Diamond			S.A.S.			2021
Current assets	$	919		$	19,531		$	315		$	20,765
Non-current assets		103			153,696			146,587			300,386
Current liabilities		(956	)		(28,511	)		(62	)		(29,529	)
Non-current liabilities		(406	)		(69,332	)		(6,606	)		(76,344	)
Net assets	$	(340	)	$	75,384		$	140,234		$	215,278

Non-controlling interests for the six months ended November 30, 2021:

	Superhero			CC Pharma			Aphria			ColCanna			November 30,
	LP			Nordic ApS			Diamond			S.A.S.			2021
Revenue	$	—		$	136		$	53,101		$	—		$	53,237
Total expenses		—			178			26,367			458			27,003
Net (loss) income		—			(42	)		26,734			(458	)		26,234
Other comprehensive (loss) income		(16,357	)		26			(2,817	)		(4,120	)		(23,268	)
Net comprehensive income	$	(16,357	)	$	(16	)	$	23,917		$	(4,578	)	$	2,966
Non-controlling interest %		32	%		25	%		49	%		10	%	NA
Net comprehensive (loss) income	$	(5,234	)	$	(4	)	$	11,719		$	(458	)	$	6,023

Non-controlling interests for the six months ended November 30, 2020:

	CC Pharma			Aphria			ColCanna			November 30,
	Nordic ApS			Diamond			S.A.S.			2020
Revenue	$	368		$	79,515		$	—		$	79,883
Total expenses		703			31,791			500			32,994
Net (loss) income		(335	)		47,724			(500	)		46,889
Other comprehensive (loss) income		—			—			—			—
Net comprehensive income	$	(335	)	$	47,724		$	(500	)	$	46,889
Non-controlling interest %		25	%		49	%		10	%	NA
Net comprehensive (loss) income	$	(85	)	$	23,385		$	(50	)	$	23,250

Commitments and contingencies (Tables)

6 Months Ended

Nov. 30, 2021

Commitments And Contingencies Disclosure [Abstract]

Schedule of Purchase and Other Commitments Maturities

	Total		2022 (remaining six months)		2023		2024		2025		2026		Thereafter
Long-term debt repayment	$	185,021	$	34,201	$	75,242	$	72,045	$	1,602	$	990	$	941
Convertible notes, principal and interest		599,090		13,756		27,512		298,422		259,400		—		—
Material purchase obligations		28,951		12,024		14,741		1,101		407		254		424
Construction commitments		3,534		3,534		—		—		—		—		—
Total	$	816,596	$	63,515	$	117,495	$	371,568	$	261,409	$	1,244	$	1,365

Summary of Future Undiscounted Payment Associated with Lease Liabilities

The following table presents the future undiscounted payment associated with lease liabilities as of November 30, 2021:

	Operating			Finance
	leases			leases
2022 (remaining six months)		2,071			1,114
2023		3,845			7,026
2024		3,236			2,061
2025		2,681			2,122
2026		2,898			2,186
Thereafter		7,242			39,586
Total minimum lease payments	$	21,973		$	54,095
Imputed interest		(4,240	)		(18,975	)
Obligations recognized	$	17,733		$	35,120

Net revenue (Tables)

6 Months Ended

Nov. 30, 2021

Revenues [Abstract]

Summary of Net Revenue

Net revenue is comprised of:

	For the three months ended November 30,						For the six months ended November 30,
	2021			2020			2021			2020
Cannabis revenue	$	73,429		$	70,155		$	163,362		$	137,275
Cannabis excise taxes		(14,654	)		(15,389	)		(34,138	)		(31,307	)
Net cannabis revenue		58,775			54,766			129,224			105,968
Beverage alcohol revenue		14,544			754			31,027			754
Beverage alcohol excise taxes		(837	)		(44	)		(1,859	)		(44	)
Net beverage alcohol revenue		13,707			710			29,168			710
Distribution revenue		68,869			73,983			136,055			140,271
Wellness revenue		13,802			—			28,729			—
Total	$	155,153		$	129,459		$	323,176		$	246,949

Cost of Goods Sold (Tables)

6 Months Ended

Nov. 30, 2021

Cost Of Goods And Services Sold [Abstract]

Summary of Cost of Goods Sold

Cost of goods sold is comprised of:

	For the three months ended November 30,				For the six months ended November 30,
	2021		2020		2021		2020
Cannabis costs	$	45,259	$	29,632	$	85,450	$	55,407
Beverage alcohol costs		5,921		281		12,583		281
Distribution costs		61,237		64,263		120,527		121,033
Wellness costs		9,970		—		20,895		—
Total	$	122,387	$	94,176	$	239,455	$	176,721

General and administrative expenses (Tables)

6 Months Ended

Nov. 30, 2021

General And Administrative Expense [Abstract]

Schedule of General and Administrative Expenses

General and administrative expenses are comprised of:

	For the three months ended November 30,				For the six months ended November 30,
	2021		2020		2021		2020
Executive compensation	$	2,237	$	2,711	$	5,327	$	4,961
Office and general		5,206		4,418		17,973		8,839
Salaries and wages		8,149		8,821		23,460		18,164
Stock-based compensation		8,253		5,489		17,670		8,339
Insurance		4,995		2,904		9,626		6,110
Professional fees		3,355		3,171		6,068		6,106
Travel and accommodation		982		525		1,774		1,252
Rent		292		234		1,058		474
Total	$	33,469	$	28,273	$	82,956	$	54,245

Non-operating income (expense) (Tables)

6 Months Ended

Nov. 30, 2021

Nonoperating Income Expense [Abstract]

Schedule of Non-Operating Income (Expense)

Non-operating income (expense) is comprised of:

	For the three months ended November 30,						For the six months ended November 30,
	2021			2020			2021			2020
Change in fair value of convertible debenture	$	56,353		$	(70,683	)	$	95,723		$	(70,343	)
Change in fair value of warrant liability		20,178			—			37,713			—
Foreign exchange loss		(10,180	)		(3,371	)		(15,904	)		(19,702	)
Loss on long-term investments		(1,833	)		(399	)		(3,508	)		(1,519	)
Gain from equity investees		—			—			1,356			—
Other non-operating (losses) gains, net		232			1,804			(1,770	)		5,556
Total	$	64,750		$	(72,649	)	$	113,610		$	(86,008	)

Fair Value Measurements (Tables)

6 Months Ended

Nov. 30, 2021

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

							November 30,
	Level 1		Level 2		Level 3		2021
Financial assets
Cash and cash equivalents	$	331,783	$	—	$	—	$	331,783
Convertible notes receivable		—		1,560		—		1,560
Equity investments measured at fair value		5,918		2,384		—		8,302
Debt securities classified under available-for-sale method		—		—		154,442		154,442
Financial liabilities
Warrant liability		—		—		40,455		40,455
Contingent consideration		—		—		62,339		62,339
APHA 24 Convertible debenture		—		—		284,724		284,724
Total recurring fair value measurements	$	337,701	$	3,944	$	541,960	$	883,605

							May 31,
	Level 1		Level 2		Level 3		2021
Financial assets
Cash and cash equivalents	$	488,466	—		—		$	488,466
Convertible notes receivable	—			2,485	—			2,485
Equity investments measured at fair value		9,251		2,934	—			12,185
Debt securities classified under available-for-sale method	—			—	—			—
Financial liabilities
Warrant liability	—		—			78,168		78,168
Contingent consideration	—		—			60,657		60,657
APHA 24 Convertible debenture	—		—			399,444		399,444
Total recurring fair value measurements	$	497,717	$	5,419	$	538,269	$	1,041,405

Schedule of Balances of Assets and Liabilities Categorized Within Level 3 of Fair Value Hierarchy Measured at Fair Value on Recurring Basis

The balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows:

	APHA 24									Debt
	Convertible			Warrant			Contingent			Securities
	Debt			Liability			Consideration			AFS			Total
Balance, May 31, 2021		(399,444	)		(78,168	)		(60,657	)		—			(538,269	)
Additions		—			—			—			170,799			170,799
Disposals		—			—			—			—			—
Unrealized gain (loss) on fair value		114,720			37,713			(1,682	)		(16,357	)		134,394
Balance, November 30, 2021	$	(284,724	)	$	(40,455	)	$	(62,339	)	$	154,442		$	(233,076	)

Schedule of Estimated Fair Value of Convertible Debenture / Warrant Liability, Contingent Consideration and Debt Securities Classified under Available-for-sale Method

Risk-free interest rate		1.40	%
Expected volatility		70	%
Expected term	3.80 years
Expected dividend yield		0.0	%
Strike price	$	5.95
Fair value of common stock	$	10.12

Financial asset / financial liability	Valuation technique	Significant unobservable input	Inputs
APHA Convertible debentures	Black-Scholes	Volatility, expected life	70% 2.5 years
Warrant liability	Black-Scholes	Volatility, expected life	70% 3.8 years
Contingent consideration	Discounted cash flows	Discount rate, achievement	5% 100%
Debt securities classified under available-for-sale method	Black-Scholes	Interest rate, conversion	20% 0% to 60%

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Segment reporting (Tables)

6 Months Ended

Nov. 30, 2021

Segment Reporting [Abstract]

Schedule of Segment Net Revenue From External Customers

Segment net revenue from external customers:

	For the three months ended November 30,				For the six months ended November 30,
		2021		2020		2021		2020
Cannabis business	$	58,775	$	54,766	$	129,224	$	105,968
Distribution business		68,869		73,983		136,055		140,271
Beverage alcohol business		13,707		710		29,168		710
Wellness business		13,802		—		28,729		—
Total	$	155,153	$	129,459	$	323,176	$	246,949

Channels of Cannabis revenue were as follows:

	For the three months ended November 30,						For the six months ended November 30,
	2021			2020			2021			2020
Revenue from Canadian medical cannabis products	$	7,929		$	6,260		$	16,303		$	12,640
Revenue from Canadian adult-use cannabis products		49,535			58,175			119,128			115,123
Revenue from wholesale cannabis products		2,259			1,440			3,959			5,232
Revenue from international cannabis products		13,706			4,280			23,972			4,280
Less excise taxes		(14,654	)		(15,389	)		(34,138	)		(31,307	)
Total	$	58,775		$	54,766		$	129,224		$	105,968

Schedule of Segment Gross Profit From External Customers

Segment gross profit from external customers:

	For the three months ended November 30,				For the six months ended November 30,
	2021		2020		2021		2020
Cannabis business	$	13,516	$	25,134	$	43,774	$	50,561
Distribution business		7,632		9,720		15,528		19,238
Beverage alcohol business		7,786		429		16,585		429
Wellness business		3,832		—		7,834		—
Total	$	32,766	$	35,283	$	83,721	$	70,228

Schedule of Geographic Net Revenue

Geographic net revenue:

	For the three months ended November 30,				For the six months ended November 30,
	2021		2020		2021		2020
North America	$	72,443	$	54,475	$	162,986	$	105,667
EMEA		74,916		73,714		150,925		138,791
Rest of World		7,794		1,270		9,265		2,491
Total	$	155,153	$	129,459	$	323,176	$	246,949

Schedule of Geographic Capital Assets

Geographic capital assets:

	November 30, 2021		May 31, 2021
North America	$	467,646	$	504,575
EMEA		132,666		140,838
Rest of World		3,937		5,285
Total	$	604,249	$	650,698

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions			6 Months Ended
	Sep. 17, 2021	Aug. 13, 2021	Nov. 30, 2021
SH Acquisition
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Common stock issued, shares	9,817,061
Acquisition of equity ownership percentage		68.00%
Convertible notes conversion percentage of shares		21.00%
MM Notes \| LIBOR
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Interest rate			6.00%
MM Notes \| LIBOR \| Floor
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Interest rate			2.50%
MM Notes \| Convertible Senior Notes Due 2028 \| SH Acquisition
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Principal amount of senior secured convertible notes		$ 165.8
Debt instrument maturity date		Aug. 17, 2028
Med Men Notes And Warrants
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Acquisition of equity ownership percentage		68.00%
Med Men Notes And Warrants \| LIBOR
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Interest rate			6.00%
Med Men Notes And Warrants \| LIBOR \| Floor
Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]
Interest rate			2.50%

Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Nov. 30, 2021	May 31, 2021
Inventory [Line Items]
Total	$ 233,020	$ 256,429
Plants
Inventory [Line Items]
Total	19,935	23,083
Dried Cannabis
Inventory [Line Items]
Total	115,970	118,269
Cannabis Trim
Inventory [Line Items]
Total	3,725	2,931
Cannabis Derivatives
Inventory [Line Items]
Total	28,215	24,158
Cannabis Vapes
Inventory [Line Items]
Total	3,193	3,791
Packaging and Other Inventory Items
Inventory [Line Items]
Total	22,768	31,462
Wellness Inventory
Inventory [Line Items]
Total	12,412	15,171
Beverage Alcohol Inventory
Inventory [Line Items]
Total	4,792	5,402
Distribution Inventory
Inventory [Line Items]
Total	$ 22,010	$ 32,162

Inventory - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
Inventory [Line Items]
Inventory valuation write down			$ 12,000
Cannabis
Inventory [Line Items]
Inventory valuation write down	$ 12,000	$ 0	$ 12,000	$ 0

Capital Assets - Schedule of Capital Assets (Details) - USD ($) $ in Thousands	Nov. 30, 2021	May 31, 2021
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 731,820	$ 727,574
Less: accumulated amortization	(127,571)	(76,876)
Total	604,249	650,698
Land
Property Plant And Equipment [Line Items]
Property and equipment, gross	26,779	28,549
Production Facility
Property Plant And Equipment [Line Items]
Property and equipment, gross	411,611	346,510
Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	236,239	215,408
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	7,444	17,059
ROU Assets Under Finance Lease
Property Plant And Equipment [Line Items]
Property and equipment, gross	34,798	34,726
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 14,949	$ 85,322

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Nov. 30, 2021	Aug. 31, 2021	May 31, 2021
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	$ 1,580,105	$ 1,658,110
Additions	123	1,038
Effect of foreign exchange	(28,115)	(79,043)
Intangible assets, Cost	1,552,113	1,580,105
Intangible assets, Accumulated depreciation	77,291	52,192
Amortization	24,807	25,099
Intangible assets, Accumulated depreciation	102,098	77,291
Intangible assets, Net book value	1,450,015	1,502,814	$ 1,605,918
Customer Relationships and Distribution Channel
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	230,510	239,810
Effect of foreign exchange	(6,240)	(9,300)
Intangible assets, Cost	224,270	230,510
Intangible assets, Accumulated depreciation	27,768	18,302
Amortization	10,904	9,466
Intangible assets, Accumulated depreciation	38,672	27,768
Intangible assets, Net book value	185,598	202,742	221,508
Licences, Permits & Applications
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	397,766	414,930
Additions	26	182
Effect of foreign exchange	(11,776)	(17,346)
Intangible assets, Cost	386,016	397,766
Intangible assets, Accumulated depreciation	1,283	1,167
Amortization	122	116
Intangible assets, Accumulated depreciation	1,405	1,283
Intangible assets, Net book value	384,611	396,483	413,763
Non-compete Agreements
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	11,794	12,453
Effect of foreign exchange		(659)
Intangible assets, Cost	11,794	11,794
Intangible assets, Accumulated depreciation	5,132	4,299
Amortization	1,188	833
Intangible assets, Accumulated depreciation	6,320	5,132
Intangible assets, Net book value	5,474	6,662	8,154
Intellectual Property, Trademarks, Know How & Brands
Finite Lived Intangible Assets [Line Items]
Intangible assets, Cost	940,035	990,917
Additions	97	856
Effect of foreign exchange	(10,099)	(51,738)
Intangible assets, Cost	930,033	940,035
Intangible assets, Accumulated depreciation	43,108	28,424
Amortization	12,593	14,684
Intangible assets, Accumulated depreciation	55,701	43,108
Intangible assets, Net book value	$ 874,332	$ 896,927	$ 962,493

Intangible Assets - Additional Information (Details) - USD ($) $ in Thousands	Nov. 30, 2021	May 31, 2021
Licences, Permits & Applications
Indefinite Lived Intangible Assets By Major Class [Line Items]
Indefinite lived intangible assets	$ 383,445	$ 412,000

Intangible Assets - Schedule of Estimated Amortization Expense (Details) $ in Thousands	Nov. 30, 2021 USD ($)
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
2022 (remaining six months)	$ 35,746
2023	63,770
2024	57,094
2025	56,091
2026	56,091
Thereafter	797,778
Total	$ 1,066,570

Goodwill - Schedule of Goodwill (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Nov. 30, 2021	May 31, 2021
Goodwill [Line Items]
Effect of foreign exchange	$ 33,754	$ 63,713
Total	2,814,163	2,832,794
Broken Coast Cannabis Ltd. \| Cannabis Business
Goodwill [Line Items]
Goodwill, acquired during period	105,963	105,963
Nuuvera Corp. \| Cannabis Business
Goodwill [Line Items]
Goodwill, acquired during period	273,606	273,606
LATAM Holdings Inc. \| Cannabis Business
Goodwill [Line Items]
Goodwill, acquired during period	63,239	63,239
CC Pharma GmbH \| Distribution Business
Goodwill [Line Items]
Goodwill, acquired during period	4,458	4,458
Sweet Water \| Beverage Alcohol Business
Goodwill [Line Items]
Goodwill, acquired during period	100,202	100,202
Tilray \| Cannabis Business
Goodwill [Line Items]
Goodwill, acquired during period	2,155,471	2,144,143
Tilray \| Hemp Business
Goodwill [Line Items]
Goodwill, acquired during period	$ 77,470	$ 77,470

Goodwill - Summary of Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Nov. 30, 2021	May 31, 2021
Assets
Goodwill-provisional	$ 2,814,163	$ 2,832,794
Aphria Inc
Assets
Cash and cash equivalents	375,673	375,673
Accounts receivable	28,054	28,054
Inventory	68,547	76,547
Prepaids and other current assets	2,960	8,960
Capital assets	136,637	136,637
Right-of-use assets, operating leases	12,606	12,606
Goodwill-provisional	2,232,941	2,221,613
Other assets	22,879	22,879
Total assets	3,959,297	3,961,969
Liabilities
Accounts payable	62,292	62,292
Accrued expenses and other current liabilities	85,120	85,120
Accrued lease obligations	21,962	21,962
Warrant liability	79,402	79,402
Deferred tax liability	233,719	236,391
Convertible notes	267,862	267,862
Other liabilities	4,034	4,034
Total liabilities	754,391	757,063
Net assets acquired	3,204,906	3,204,906
Licenses \| Aphria Inc
Assets
Business combination indefinite lived intangible assets	200,000	200,000
Distribution Channel \| Aphria Inc
Assets
Business combination intangibles	404,000	404,000
Customer Relationships \| Aphria Inc
Assets
Business combination intangibles	59,000	59,000
Know How \| Aphria Inc
Assets
Business combination intangibles	115,000	115,000
Brands \| Aphria Inc
Assets
Business combination intangibles	$ 301,000	$ 301,000

Goodwill - Summary of Fair Values of Assets Acquired and Liabilities Assumed (Parenthetical) (Details) - Aphria Inc	6 Months Ended	12 Months Ended
	Nov. 30, 2021	May 31, 2021
Distribution Channel
Business Acquisition [Line Items]
Estimated useful life of intangible assets	15 years	15 years
Customer Relationships
Business Acquisition [Line Items]
Estimated useful life of intangible assets	15 years	15 years
Know How
Business Acquisition [Line Items]
Estimated useful life of intangible assets	5 years	5 years
Brands \| Minimum
Business Acquisition [Line Items]
Estimated useful life of intangible assets	10 years	10 years
Brands \| Maximum
Business Acquisition [Line Items]
Estimated useful life of intangible assets	25 years	25 years

Long-term Investments - Schedule of Long-term Investments (Details) - USD ($) $ in Thousands	Nov. 30, 2021	May 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Debt securities classified under available-for-sale method	$ 154,442
Equity investments measured at fair value		$ 12,185
Equity investments under measurement alternative	5,500	5,500
Total investments in debt and equity securities	168,244	17,685
Level 1
Schedule Of Available For Sale Securities [Line Items]
Equity investments measured at fair value	5,918	9,251
Level 2
Schedule Of Available For Sale Securities [Line Items]
Equity investments measured at fair value	$ 2,384	$ 2,934

Long-term Investments - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
Schedule Of Available For Sale Securities [Line Items]
Unrealized gains (losses) on equity investments	$ (1,806,000)	$ (399,000)	$ (3,883,000)	$ (1,326,000)
Impairments or adjustments equity investments under measurement alternative	0	$ 0	0	$ 0
Investment in Equities
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale securities, allowance for credit loss	0		0
Credit loss expenses	0		0
Long-term Investments \| Investment in Equities
Schedule Of Available For Sale Securities [Line Items]
Available-for-sale securities, Gross unrealized loss	$ 16,357,000		$ 16,357,000
MM Notes
Schedule Of Available For Sale Securities [Line Items]
Convertible debt instruments contractual maturity			2028
MM Notes \| LIBOR
Schedule Of Available For Sale Securities [Line Items]
Interest rate			6.00%
MM Notes \| LIBOR \| Floor
Schedule Of Available For Sale Securities [Line Items]
Interest rate			2.50%

Long-term Investments - Schedule of Weighted Average Assumptions, Debt Securities under Available-for-Sale (Details) - Debt Securities - Level 3	Nov. 30, 2021 yr
Expected Term \| Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	0.4
Expected Term \| Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	6.7
Expected Volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	70
Effective Interest Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	20.4
Expected Dividend Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	0.0
Probability of Conversion \| Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	0
Probability of Conversion \| Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	60
Strike Price \| Minimum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	0.15
Strike Price \| Maximum
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	4.29
Fair Value of Common Stock
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	0.22

Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Nov. 30, 2021	May 31, 2021
Accounts Payable And Accrued Liabilities Current And Noncurrent [Abstract]
Trade payables	$ 64,980	$ 57,706
Accrued liabilities	62,915	112,594
Accrued payroll and employment related taxes	18,403	19,390
Income taxes payable	14,957	14,764
Accrued interest	6,764	148
Other accruals	281	8,211
Total	$ 168,300	$ 212,813

Bank Indebtedness - Additional Information (Details)	6 Months Ended
Bank Indebtedness - Additional Information (Details)	Nov. 30, 2021 CAD ($) Lineofcredit	Nov. 30, 2021 EUR (€) Lineofcredit	Nov. 30, 2021 USD ($)	Nov. 30, 2021 CAD ($)	Nov. 30, 2021 EUR (€)
Line Of Credit Facility [Line Items]
Operating line of credit \| $	$ 1,000
Line of credit \| $			$ 0
CC Pharma
Line Of Credit Facility [Line Items]
Line of credit				$ 8,264	€ 7,353
Number of operating lines of credit \| Lineofcredit	3	3
Available credit amount \| €		€ 12,000
Four Twenty Corporation (“420”) \| Revolving Credit Facility
Line Of Credit Facility [Line Items]
Line of credit \| $			$ 0
Operating Lines of Credit One \| CC Pharma
Line Of Credit Facility [Line Items]
Operating line of credit \| €		8,000
Operating Lines of Credit Two \| CC Pharma
Line Of Credit Facility [Line Items]
Operating line of credit \| €		3,500
Operating Lines of Credit Three \| CC Pharma
Line Of Credit Facility [Line Items]
Operating line of credit \| €		€ 500
Prime Rate
Line Of Credit Facility [Line Items]
Interest rate	7.50%	7.50%
Euro Over Night Index Average Plus \| Operating Lines of Credit One \| CC Pharma
Line Of Credit Facility [Line Items]
Interest rate			1.79%	1.79%	1.79%
Interest rate			1.79%	1.79%	1.79%
Euro Interbank Offered Rate Plus \| Operating Lines of Credit Two \| CC Pharma
Line Of Credit Facility [Line Items]
Interest rate			3.682%	3.682%	3.682%
Interest rate			3.682%	3.682%	3.682%
EURIBOR \| Four Twenty Corporation (“420”) \| Revolving Credit Facility
Line Of Credit Facility [Line Items]
Line of credit \| $			$ 20,000,000

Long-term Debt - Schedule of Net Carrying Amount of Long-term Debt Instruments (Details) - USD ($) $ in Thousands	Nov. 30, 2021	May 31, 2021
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 185,021	$ 206,169
Unamortized financing fees	(1,692)	(2,061)
Net carrying amount	183,329	204,108
Less principal portion included in current liabilities	(31,510)	(36,622)
Total noncurrent portion of long-term debt	151,819	167,486
Credit Facility Due in November 2022
Debt Instrument [Line Items]
Carrying amount of long-term debt	56,160	62,964
Term Loan Due in July 2023
Debt Instrument [Line Items]
Carrying amount of long-term debt	13,015	14,335
Term Loan Due in April 2022
Debt Instrument [Line Items]
Carrying amount of long-term debt	15,446	17,117
Term Loan Due in August 2026
Debt Instrument [Line Items]
Carrying amount of long-term debt	505	587
Mortgage Payable due in August 2026
Debt Instrument [Line Items]
Carrying amount of long-term debt	2,354	2,562
Vendor-Take-Back Mortgage Due in June 2021
Debt Instrument [Line Items]
Carrying amount of long-term debt		92
Term Loan Due in December 2023 \| Euro Interbank Offered Rate Plus 1.79%
Debt Instrument [Line Items]
Carrying amount of long-term debt	2,543	3,356
Term Loan Due in December 2023 \| Euro Interbank Offered Rate Plus 2.68%
Debt Instrument [Line Items]
Carrying amount of long-term debt	2,543	3,356
Term Loan Due in April 2025 \| Euro Interbank Offered Rate Plus 2.00%
Debt Instrument [Line Items]
Carrying amount of long-term debt	1,491	1,831
Term Loan Due in June 2025 \| Euro Interbank Offered Rate Plus 2.00%
Debt Instrument [Line Items]
Carrying amount of long-term debt	1,589	1,831
Term Loan Due in March 2024 \| EURIBOR
Debt Instrument [Line Items]
Carrying amount of long-term debt	$ 89,375	$ 98,138

Long-term Debt - Schedule of Net Carrying Amount of Long-term Debt Instruments (Parenthetical) (Details) € in Thousands, $ in Thousands, $ in Thousands	6 Months Ended
	Nov. 30, 2021 USD ($)	Nov. 30, 2021 EUR (€)	Nov. 30, 2021 CAD ($)	Nov. 30, 2021 EUR (€)
Credit Facility Due in November 2022 \| Canadian Prime Interest Rate
Debt Instrument [Line Items]
Credit facility amount			$ 80,000
Debt instrument term	3 years	3 years
Debt instrument amortization period	10 years	10 years
Term Loan Due in July 2023 \| Canadian Five Year Bond Interest Rate Plus 2.73
Debt Instrument [Line Items]
Credit facility amount			$ 25,000
Debt instrument term	5 years	5 years
Debt instrument amortization period	15 years	15 years
Debt instrument interest rate percentage	2.73%		2.73%	2.73%
Term Loan Due in July 2023 \| Canadian Five Year Bond Interest Rate Plus 2.73 \| Minimum
Debt Instrument [Line Items]
Debt instrument interest rate percentage	4.50%		4.50%	4.50%
Term Loan Due in April 2022
Debt Instrument [Line Items]
Credit facility amount			$ 25,000
Debt instrument term	5 years	5 years
Debt instrument amortization period	15 years	15 years
Debt instrument interest rate percentage	3.95%		3.95%	3.95%
Repayment of instalments including interest	$ 188
Term Loan Due in August 2026
Debt Instrument [Line Items]
Credit facility amount			$ 1,250
Debt instrument term	5 years	5 years
Debt instrument amortization period	10 years	10 years
Debt instrument interest rate percentage	3.85%		3.85%	3.85%
Repayment of instalments including interest	$ 13
Mortgage Payable due in August 2026
Debt Instrument [Line Items]
Credit facility amount			$ 3,750
Debt instrument term	5 years	5 years
Debt instrument amortization period	20 years	20 years
Debt instrument interest rate percentage	3.85%		3.85%	3.85%
Repayment of instalments including interest	$ 23
Vendor-Take-Back Mortgage Due in June 2021
Debt Instrument [Line Items]
Credit facility amount			$ 2,850
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	6.75%		6.75%	6.75%
Repayment of instalments including interest	$ 56
Term Loan Due in December 2023 \| Euro Interbank Offered Rate Plus 1.79%
Debt Instrument [Line Items]
Credit facility amount \| €				€ 5,000
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	1.79%		1.79%	1.79%
Repayment of instalments including interest \| €		€ 250
Term Loan Due in December 2023 \| Euro Interbank Offered Rate Plus 2.68%
Debt Instrument [Line Items]
Credit facility amount \| €				€ 5,000
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	2.68%		2.68%	2.68%
Repayment of instalments including interest \| €		€ 250
Term Loan Due in April 2025 \| Euro Interbank Offered Rate Plus 2.00%
Debt Instrument [Line Items]
Credit facility amount \| €				€ 1,500
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	2.00%		2.00%	2.00%
Repayment of instalments including interest \| €		€ 98
Term Loan Due in June 2025 \| Euro Interbank Offered Rate Plus 2.00%
Debt Instrument [Line Items]
Credit facility amount \| €				€ 1,500
Debt instrument term	5 years	5 years
Debt instrument interest rate percentage	2.00%		2.00%	2.00%
Repayment of instalments including interest \| €		€ 98
Term Loan Due in March 2024 \| EURIBOR
Debt Instrument [Line Items]
Credit facility amount	$ 100,000
Debt instrument term	3 years	3 years
Long-term debt, repayments of principal in next rolling twelve months	$ 7,500
Long-term debt, repayments of principal in rolling year two	10,000
Long-term debt, repayments of principal in rolling year three	$ 10,000

Convertible Debentures - Schedule of Components of Net Carrying Amount of Convertible Debentures (Detail) - USD ($) $ in Thousands	Nov. 30, 2021	May 31, 2021
Debt Instrument [Line Items]
Total	$ 554,854	$ 667,624
5.25% Convertible Notes ("APHA 24")
Debt Instrument [Line Items]
Total	284,724	399,444
5.00% Convertible Notes ("TLRY 23")
Debt Instrument [Line Items]
Total	$ 270,130	$ 268,180

Convertible Debentures - Schedule of Convertible Debentures - APHA 24 (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Nov. 30, 2021	May 31, 2021
Debt Instrument [Line Items]
Opening balance	$ 667,624
Closing balance	554,854	$ 667,624
5.25% Convertible Notes ("APHA 24")
Debt Instrument [Line Items]
Opening balance	399,444
Debt settlement	(90,760)	(90,760)
Fair value adjustment	25,484	140,204
Closing balance	284,724	399,444
5.25% Convertible Notes ("APHA 24") \| 5.25% Contractual Debenture
Debt Instrument [Line Items]
Opening balance	$ 350,000	350,000
Closing balance		$ 350,000

Convertible Debentures - Additional Information (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Nov. 30, 2021 shares Tradingday $ / shares	May 31, 2021 USD ($) $ / shares	May 31, 2020 USD ($)
Debt Instrument [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001
Estimated fair value of APHA 24 convertible debenture per convertible debenture	1,098
5.25% Convertible Notes ("APHA 24")
Debt Instrument [Line Items]
Debt instrument initial conversion price per share	$ 11.20
Debt instrument convertible description	Holders of the APHA 24 may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time between December 1, 2023 to the maturity date.
Debt instrument, convertible, terms of conversion feature	(a) the last reported sales price of the common shares for at least 20 trading days during a period of 30 consecutive trading days immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (b) during the five-business day period after any five consecutive trading day period (the “measurement period”) in which the trading price per $1 principal amount of the APHA 24 for each trading day of the measurement period is less than 98% of the product of the last reported sale price of the Company’s common shares and the conversion rate on each such trading day; (c) the Company calls any or all of the APHA 24 for redemption or; (d) upon occurrence of specified corporate event.
Debt instrument, convertible, minimum trading days \| Tradingday	20
Debt instrument, convertible, consecutive trading days \| Tradingday	30
Debt instrument, convertible, threshold percentage of stock price trigger	130.00%
Debt instrument, convertible, minimum threshold percentage during measurement period	98.00%
Percentage of redemption value on principal plus accrued and unpaid interest	100.00%
5.00% Convertible Notes ("TLRY 23")
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Ratio	5.9735
Debt instrument initial conversion price per share	$ 167.41
Debt instrument, convertible, number of common stock \| shares	1,659,737
Credit facility amount \| $		$ 277,856	$ 0
Tilray \| 5.25% Convertible Notes ("APHA 24") \| Common Stock
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Ratio	89.31162364
Common stock, par value	$ 0.0001

Convertible Debentures - Schedule of Estimated Fair Value of Convertible Debenture (Details)	Nov. 30, 2021 yr
Expected Term
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	2.5
APHA 24 \| Level 3 \| Risk-free Interest Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	1.43
APHA 24 \| Level 3 \| Expected Volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	70
APHA 24 \| Level 3 \| Expected Term
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	2.5
APHA 24 \| Level 3 \| Expected Dividend Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	0.0

Convertible Debentures - Schedule of Convertible Debentures - TLRY 23 (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Nov. 30, 2021	May 31, 2021
Debt Instrument [Line Items]
Opening balance	$ 667,624
Closing balance	554,854	$ 667,624
5.00% Convertible Notes ("TLRY 23")
Debt Instrument [Line Items]
Opening balance	268,180
Unamortized discount	(7,726)	(9,676)
Closing balance	270,130	268,180
5.00% Convertible Notes ("TLRY 23") \| 5.25% Contractual Debenture
Debt Instrument [Line Items]
Opening balance	$ 277,856	277,856
Closing balance		$ 277,856

Warrant Liability - Schedule of Warrant Details (Details) - $ / shares	6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	May 31, 2021	May 31, 2020
Class Of Warrant Or Right [Line Items]
Exercise Price	$ 7.47	$ 8.91	$ 7.41	$ 8.91
Beginning Balance	12,203,651	5,994,651
Issued	0	0
Exercised/Expired	(166,000)
Ending Balance	12,037,651	5,994,651
Warrant Expiring September 26, 2021
Class Of Warrant Or Right [Line Items]
Classification	Equity
Exercise Price	$ 3.08
Beginning Balance	166,000
Exercised/Expired	(166,000)
Warrant Expiring January 30, 2022
Class Of Warrant Or Right [Line Items]
Classification	Equity
Exercise Price	$ 9.08
Beginning Balance	5,828,651
Ending Balance	5,828,651
Warrant Expiring March 17, 2025
Class Of Warrant Or Right [Line Items]
Classification	Liability
Exercise Price	$ 5.95
Beginning Balance	6,209,000
Ending Balance	6,209,000

Warrant Liability - Schedule of Warrants Outstanding (Details) - $ / shares	6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020
Warrants And Rights Note Disclosure [Abstract]
Beginning Balance	12,203,651	5,994,651
Exercised during the period, Number of warrants	0	0
Issued during the period, Number of warrants	0	0
Cancelled during the period, Number of warrants	0	0
Expired during the period, Number of warrants	(166,000)	0
Ending Balance	12,037,651	5,994,651
Outstanding, opening of the period, weighted average price	$ 7.41	$ 8.91
Exercised during the period, weighted average price	0	0
Issued during the period, weighted average price	0	0
Cancelled during the period, weighted average price	0	0
Expired during the period, weighted average price	3.08	0
Outstanding, ending of the period, weighted average price	$ 7.47	$ 8.91

Warrant Liability - Additional Information (Details)	Nov. 30, 2021 $ / shares
Level 3
Class Of Warrant Or Right [Line Items]
Estimated fair value of warrant liability per warrant	$ 6.51

Warrant Liability - Schedule of Estimated Fair Value of Warrant Liability (Details)	Nov. 30, 2021 USD ($) yr
Expected Term
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input \| yr	3.8
Warrant \| Risk-free Interest Rate \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	1.40
Warrant \| Expected Volatility \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	70
Warrant \| Expected Term \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input \| yr	3.80
Warrant \| Expected Dividend Yield \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input	0.0
Warrant \| Strike Price \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input \| $	5.95
Warrant \| Fair Value of Common Stock \| Level 3
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrant and rights measurement input \| $	10.12

Stock-Based Compensation - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated share-based compensation expenses	$ 8,253	$ 5,489	$ 17,670	$ 8,339
Number of RSUs granted	69,508		1,414,666
Number of RSUs vested	0	0	0	0
Accelerated fully vested	0	0	679,000	0
Aphria’s Predecessor Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted	0		0
Number of RSUs granted	0		0

Stock-Based Compensation - Summary of Stock Based Compensation Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total	$ 8,253	$ 5,489	$ 17,670	$ 8,339
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total	1,939	879	4,695	2,250
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total	$ 6,314	$ 4,610	$ 12,975	$ 6,089

Accumulated Other Comprehensive Income (Loss) - Schedule of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended
	Nov. 30, 2021	Aug. 31, 2021
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	$ 51,247	$ 152,668
Other comprehensive loss	(41,652)	(101,421)
Ending balance	9,595	51,247
Foreign Currency Translation Gain (Loss) [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	55,645	156,417
Other comprehensive loss	(32,367)	(100,772)
Ending balance	23,278	55,645
Unrealized Loss on Convertible Notes Receivables [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning balance	(4,398)	(3,749)
Other comprehensive loss	52	(649)
Ending balance	(4,346)	$ (4,398)
Unrealized Loss on Available-for-sale Debt Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Other comprehensive loss	(16,357)
Ending balance	(16,357)
Non-controlling Interests
Accumulated Other Comprehensive Income Loss [Line Items]
Other comprehensive loss	7,020
Ending balance	$ 7,020

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

Non-controlling Interests - Additional Information (Details) $ in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021 USD ($)	Nov. 30, 2021 CAD ($)	Nov. 30, 2021 USD ($)	Nov. 30, 2021 CAD ($)
SH Acquisition
Minority Interest [Line Items]
Cash contributions	$ 0		$ 117,804
Aphria Diamond
Minority Interest [Line Items]
Dividends paid		$ 70,000	$ 56,630	$ 70,000

Non-controlling Interests - Summary of Information Relating to Company's Subsidiaries (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020	May 31, 2021
Minority Interest [Line Items]
Current assets	$ 708,278		$ 708,278		$ 883,609
Current liabilities	(314,928)		(314,928)		(401,241)
Revenue	155,153	$ 129,459	323,176	$ 246,949
Shareholders of Tilray Inc.	(201)	(99,900)	(41,850)	(134,243)
Other comprehensive (loss) income	(48,672)	(910)	(150,093)	475
Shareholders of Tilray Inc.	(41,853)	(100,810)	(184,923)	(133,768)
Net comprehensive (loss) income	(1,022)	$ 10,651	6,023	23,250
Non-controlling Interests
Minority Interest [Line Items]
Current assets	83,870		83,870		20,765
Non-current assets	452,532		452,532		300,386
Current liabilities	(140,708)		(140,708)		(29,529)
Non-current liabilities	(63,279)		(63,279)		(76,344)
Net assets	332,415		332,415		215,278
Revenue			53,237	79,883
Total expenses			27,003	32,994
Shareholders of Tilray Inc.			26,234	46,889
Other comprehensive (loss) income			(23,268)
Shareholders of Tilray Inc.			2,966	46,889
Net comprehensive (loss) income			6,023	23,250
Non-controlling Interests \| SH Acquisition
Minority Interest [Line Items]
Non-current assets	154,442		154,442
Net assets	$ 154,442		154,442
Other comprehensive (loss) income			(16,357)
Shareholders of Tilray Inc.			$ (16,357)
Non-controlling interest %	32.00%		32.00%
Net comprehensive (loss) income			$ (5,234)
Non-controlling Interests \| CC Pharma Nordic ApS
Minority Interest [Line Items]
Current assets	$ 629		629		919
Non-current assets	134		134		103
Current liabilities	(709)		(709)		(956)
Non-current liabilities	(410)		(410)		(406)
Net assets	$ (356)		(356)		(340)
Revenue			136	368
Total expenses			178	703
Shareholders of Tilray Inc.			(42)	(335)
Other comprehensive (loss) income			26
Shareholders of Tilray Inc.			$ (16)	$ (335)
Non-controlling interest %	25.00%	25.00%	25.00%	25.00%
Net comprehensive (loss) income			$ (4)	$ (85)
Non-controlling Interests \| Aphria Diamond
Minority Interest [Line Items]
Current assets	$ 82,882		82,882		19,531
Non-current assets	156,004		156,004		153,696
Current liabilities	(133,360)		(133,360)		(28,511)
Non-current liabilities	(62,853)		(62,853)		(69,332)
Net assets	$ 42,673		42,673		75,384
Revenue			53,101	79,515
Total expenses			26,367	31,791
Shareholders of Tilray Inc.			26,734	47,724
Other comprehensive (loss) income			(2,817)
Shareholders of Tilray Inc.			$ 23,917	$ 47,724
Non-controlling interest %	49.00%	49.00%	49.00%	49.00%
Net comprehensive (loss) income			$ 11,719	$ 23,385
Non-controlling Interests \| ColCanna S.A.S.
Minority Interest [Line Items]
Current assets	$ 359		359		315
Non-current assets	141,952		141,952		146,587
Current liabilities	(6,639)		(6,639)		(62)
Non-current liabilities	(16)		(16)		(6,606)
Net assets	$ 135,656		135,656		$ 140,234
Total expenses			458	500
Shareholders of Tilray Inc.			(458)	(500)
Other comprehensive (loss) income			(4,120)
Shareholders of Tilray Inc.			$ (4,578)	$ (500)
Non-controlling interest %	10.00%	10.00%	10.00%	10.00%
Net comprehensive (loss) income			$ (458)	$ (50)

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ (5,671)	$ (14,192)	$ (909)	$ (20,017)

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Commitments and Contingencies - Schedule of Purchase and Other Commitments Maturities (Details) $ in Thousands	Nov. 30, 2021 USD ($)
Other Commitments [Line Items]
Total	$ 816,596
2022 (remaining six months)	63,515
2023	117,495
2024	371,568
2025	261,409
2026	1,244
Thereafter	1,365
Long-term Debt Repayment
Other Commitments [Line Items]
Total	185,021
2022 (remaining six months)	34,201
2023	75,242
2024	72,045
2025	1,602
2026	990
Thereafter	941
Convertible Notes, Principal and Interest
Other Commitments [Line Items]
Total	599,090
2022 (remaining six months)	13,756
2023	27,512
2024	298,422
2025	259,400
Material Purchase Obligations
Other Commitments [Line Items]
Total	28,951
2022 (remaining six months)	12,024
2023	14,741
2024	1,101
2025	407
2026	254
Thereafter	424
Construction Commitments
Other Commitments [Line Items]
Total	3,534
2022 (remaining six months)	$ 3,534

Commitments and Contingencies - Additional Information (Details) - ABG Intermediate Holdings 2, LLC $ in Thousands	Nov. 10, 2021 USD ($) shares
Other Commitments [Line Items]
Guaranteed royalty payments terminated	$ 6,600
Royalty termination fee	3,925
Royalty termination cash payment	$ 1,500
Class 2 Common Shares
Other Commitments [Line Items]
Royalty termination shares issued \| shares	215,901

Commitments and Contingencies - Summary of Future Undiscounted Payment Associated with Lease Liabilities (Details) $ in Thousands	6 Months Ended
	Nov. 30, 2021 USD ($)
Operating leases
2022 (remaining six months)	$ 2,071
2023	3,845
2024	3,236
2025	2,681
2026	2,898
Thereafter	7,242
Total minimum lease payments	21,973
Imputed interest	(4,240)
Obligations recognized	$ 17,733
Operating Lease Liability Statement Of Financial Position [Extensible List]	tlry:OperatingLeaseLiabilityMember
Finance leases
2022 (remaining six months)	$ 1,114
2023	7,026
2024	2,061
2025	2,122
2026	2,186
Thereafter	39,586
Total minimum lease payments	54,095
Imputed interest	(18,975)
Obligations recognized	$ 35,120
Finance Lease Liability Statement Of Financial Position [Extensible List]	tlry:FinanceLeaseLiabilityMember

Net Revenue - Additional Information (Details)	6 Months Ended
Net Revenue - Additional Information (Details)	Nov. 30, 2021 Segment
Revenues [Abstract]
Number of operating segments	4

Net Revenue - Summary of Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
Net revenue	$ 155,153	$ 129,459	$ 323,176	$ 246,949
Cannabis Revenue
Net revenue	73,429	70,155	163,362	137,275
Cannabis Excise Taxes
Net revenue	(14,654)	(15,389)	(34,138)	(31,307)
Net Cannabis Revenue
Net revenue	58,775	54,766	129,224	105,968
Beverage Alcohol Revenue
Net revenue	14,544	754	31,027	754
Beverage Alcohol Excise Taxes
Net revenue	(837)	(44)	(1,859)	(44)
Net Beverage Alcohol Revenue
Net revenue	13,707	710	29,168	710
Distribution Revenue
Net revenue	68,869	$ 73,983	136,055	$ 140,271
Wellness Revenue
Net revenue	$ 13,802		$ 28,729

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Cost of Goods Sold - Summary of Cost of Goods Sold (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
Cost Of Goods And Services Sold [Abstract]
Cannabis costs	$ 45,259	$ 29,632	$ 85,450	$ 55,407
Beverage alcohol costs	5,921	281	12,583	281
Distribution costs	61,237	64,263	120,527	121,033
Wellness costs	9,970		20,895
Total	$ 122,387	$ 94,176	$ 239,455	$ 176,721

General and Administrative Expenses - Schedule of General and Administrative Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
General And Administrative Expense [Abstract]
Executive compensation	$ 2,237	$ 2,711	$ 5,327	$ 4,961
Office and general	5,206	4,418	17,973	8,839
Salaries and wages	8,149	8,821	23,460	18,164
Stock-based compensation	8,253	5,489	17,670	8,339
Insurance	4,995	2,904	9,626	6,110
Professional fees	3,355	3,171	6,068	6,106
Travel and accommodation	982	525	1,774	1,252
Rent	292	234	1,058	474
Total	$ 33,469	$ 28,273	$ 82,956	$ 54,245

Non-operating income (expense) - Schedule of Non-Operating Income (Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
Nonoperating Income Expense [Abstract]
Change in fair value of convertible debenture	$ 56,353	$ (70,683)	$ 95,723	$ (70,343)
Change in fair value of warrant liability	20,178		37,713
Foreign exchange loss	(10,180)	(3,371)	(15,904)	(19,702)
Loss on long-term investments	(1,833)	(399)	(3,508)	(1,519)
Gain from equity investees			1,356
Other non-operating (losses) gains, net	232	1,804	(1,770)	5,556
Total	$ 64,750	$ (72,649)	$ 113,610	$ (86,008)

Fair Value Measurements - Additional Information (Details) $ in Thousands	Nov. 30, 2021 USD ($)	May 31, 2021 USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Long-term debt, subject to fixed interest rates	$ 18,305	$ 20,358
Discount Rate
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Business combination, contingent consideration, liability, measurement input	0.05

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Nov. 30, 2021	May 31, 2021
Financial assets
Equity investments measured at fair value		$ 12,185
Debt securities classified under available-for-sale method	$ 154,442
Financial liabilities
Contingent consideration	62,339	60,657
Convertible debenture	554,854	667,624
Fair Value, Measurements, Recurring
Financial assets
Cash and cash equivalents	331,783	488,466
Convertible notes receivable	1,560	2,485
Equity investments measured at fair value	8,302
Debt securities classified under available-for-sale method	154,442
Financial liabilities
Warrant liability	40,455	78,168
Contingent consideration	62,339	60,657
Total recurring fair value measurements	883,605	1,041,405
Fair Value, Measurements, Recurring \| APHA 24 Convertible Debenture
Financial liabilities
Convertible debenture	284,724	399,444
Level 1
Financial assets
Equity investments measured at fair value	5,918	9,251
Level 1 \| Fair Value, Measurements, Recurring
Financial assets
Cash and cash equivalents	331,783	488,466
Equity investments measured at fair value	5,918
Financial liabilities
Total recurring fair value measurements	337,701	497,717
Level 2
Financial assets
Equity investments measured at fair value	2,384	2,934
Level 2 \| Fair Value, Measurements, Recurring
Financial assets
Convertible notes receivable	1,560	2,485
Equity investments measured at fair value	2,384
Financial liabilities
Total recurring fair value measurements	3,944	5,419
Level 3 \| Fair Value, Measurements, Recurring
Financial assets
Debt securities classified under available-for-sale method	154,442
Financial liabilities
Warrant liability	40,455	78,168
Contingent consideration	62,339	60,657
Total recurring fair value measurements	541,960	538,269
Level 3 \| Fair Value, Measurements, Recurring \| APHA 24 Convertible Debenture
Financial liabilities
Convertible debenture	$ 284,724	$ 399,444

Fair Value Measurements - Schedule of Balances of Assets and Liabilities Categorized Within Level 3 of Fair Value Hierarchy Measured at Fair Value on Recurring Basis (Details) - Level 3 - Fair Value, Measurements, Recurring $ in Thousands	6 Months Ended
	Nov. 30, 2021 USD ($)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Beginning balance	$ (538,269)
Additions	170,799
Unrealized gain (loss) on fair value	134,394
Ending balance	(233,076)
APHA 24 Convertible Debenture
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Beginning balance	(399,444)
Unrealized gain (loss) on fair value	114,720
Ending balance	(284,724)
Warrant Liability
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Beginning balance	(78,168)
Unrealized gain (loss) on fair value	37,713
Ending balance	(40,455)
Contingent Consideration
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Beginning balance	(60,657)
Unrealized gain (loss) on fair value	(1,682)
Ending balance	(62,339)
Debt Securities AFS
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Additions	170,799
Unrealized gain (loss) on fair value	(16,357)
Ending balance	$ 154,442

Fair Value Measurements - Schedule of Financial Assets and Liabilities Measurement Inputs and Valuation Techniques (Details)	6 Months Ended
	Nov. 30, 2021 yr
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt Instrument, Valuation Technique [Extensible Enumeration]	http://www.tilray.com/#ValuationTechniqueBlackScholesMember
Warrants and Rights Outstanding, Valuation Technique [Extensible Enumeration]	http://www.tilray.com/#ValuationTechniqueBlackScholesMember
Business Combination, Contingent Consideration, Liability, Valuation Technique [Extensible Enumeration]	us-gaap:ValuationTechniqueDiscountedCashFlowMember
Debt Securities Classified under Available-for-sale Valuation Technique [Extensible List]	http://www.tilray.com/#ValuationTechniqueBlackScholesMember
Volatility [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Measurement input	0.70
Warrant and rights measurement input	0.70
Expected Term
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Measurement input	2.5
Warrant and rights measurement input	3.8
Discount Rate
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent consideration	0.05
Achievement [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Contingent consideration	1.00
Interest Rate [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt securities classified under available-for-sale method	0.20
Conversion [Member] \| Minimum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt securities classified under available-for-sale method	0.00
Conversion [Member] \| Maximum
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Debt securities classified under available-for-sale method	0.60

Segment Reporting - Additional Information (Details)	3 Months Ended		6 Months Ended
Segment Reporting - Additional Information (Details)	Nov. 30, 2021 Customer	Nov. 30, 2020 Customer	Nov. 30, 2021 Segment Customer	Nov. 30, 2020 Customer
Segment Reporting Information [Line Items]
Number of operating segments			4
Number of reportable segments			4
Number of major customers \| Customer	0	0	0	0
Customer Concentration Risk \| Revenue \| Major Customers
Segment Reporting Information [Line Items]
Concentration risk, percentage	10.00%	10.00%	10.00%	10.00%

Segment Reporting - Schedule of Segment Net Revenue From External Customers (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
Segment Reporting Information [Line Items]
Revenue from external customers	$ 155,153	$ 129,459	$ 323,176	$ 246,949
Cannabis Business
Segment Reporting Information [Line Items]
Revenue from external customers	58,775	54,766	129,224	105,968
Distribution Business
Segment Reporting Information [Line Items]
Revenue from external customers	68,869	73,983	136,055	140,271
Beverage Alcohol Business
Segment Reporting Information [Line Items]
Revenue from external customers	13,707	$ 710	29,168	$ 710
Wellness Business
Segment Reporting Information [Line Items]
Revenue from external customers	$ 13,802		$ 28,729

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Segment Reporting - Schedule of Segment Gross Profit From External Customers (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
Segment Reporting Information [Line Items]
Total gross profit	$ 32,766	$ 35,283	$ 83,721	$ 70,228
Cannabis Business
Segment Reporting Information [Line Items]
Total gross profit	13,516	25,134	43,774	50,561
Distribution Business
Segment Reporting Information [Line Items]
Total gross profit	7,632	9,720	15,528	19,238
Beverage Alcohol Business
Segment Reporting Information [Line Items]
Total gross profit	7,786	$ 429	16,585	$ 429
Wellness Business
Segment Reporting Information [Line Items]
Total gross profit	$ 3,832		$ 7,834

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

Segment Reporting - Summary of Channels of Cannabis Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
Segment Reporting Information [Line Items]
Net revenue	$ 155,153	$ 129,459	$ 323,176	$ 246,949
Total	155,153	129,459	323,176	246,949
Cannabis
Segment Reporting Information [Line Items]
Less excise taxes	(14,654)	(15,389)	(34,138)	(31,307)
Total	58,775	54,766	129,224	105,968
Cannabis \| Revenue from Canadian Medical Cannabis Products
Segment Reporting Information [Line Items]
Net revenue	7,929	6,260	16,303	12,640
Cannabis \| Revenue from Canadian Adult-use Cannabis Products
Segment Reporting Information [Line Items]
Net revenue	49,535	58,175	119,128	115,123
Cannabis \| Revenue from Wholesale Cannabis Products
Segment Reporting Information [Line Items]
Net revenue	2,259	1,440	3,959	5,232
Cannabis \| Revenue from International Cannabis Products
Segment Reporting Information [Line Items]
Net revenue	$ 13,706	$ 4,280	$ 23,972	$ 4,280

Segment Reporting - Schedule of Geographic Net Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Nov. 30, 2021	Nov. 30, 2020	Nov. 30, 2021	Nov. 30, 2020
Segment Reporting Information [Line Items]
Total net revenue	$ 155,153	$ 129,459	$ 323,176	$ 246,949
North America
Segment Reporting Information [Line Items]
Total net revenue	72,443	54,475	162,986	105,667
EMEA
Segment Reporting Information [Line Items]
Total net revenue	74,916	73,714	150,925	138,791
Rest of World
Segment Reporting Information [Line Items]
Total net revenue	$ 7,794	$ 1,270	$ 9,265	$ 2,491

- Definition

+ References

+ Details

Segment Reporting - Schedule of Geographic Capital Assets (Details) - USD ($) $ in Thousands	Nov. 30, 2021	May 31, 2021
Segment Reporting Information [Line Items]
Capital assets	$ 604,249	$ 650,698
North America
Segment Reporting Information [Line Items]
Capital assets	467,646	504,575
EMEA
Segment Reporting Information [Line Items]
Capital assets	132,666	140,838
Rest of World
Segment Reporting Information [Line Items]
Capital assets	$ 3,937	$ 5,285

Subsequent Events - Additional Information (Details) - USD ($)	Dec. 17, 2021	Dec. 07, 2021	Dec. 01, 2021	Nov. 30, 2021	May 31, 2021
Subsequent Event [Line Items]
Carrying amount of long-term debt				$ 185,021,000	$ 206,169,000
Line of credit				$ 0
Subsequent Event \| Facility Amendment \| Bank of Montreal
Subsequent Event [Line Items]
Current line of credit		$ 30,000,000
Line of credit		10,000,000
Subsequent Event \| Long-Term Debt \| Facility Amendment \| Bank of Montreal
Subsequent Event [Line Items]
Carrying amount of long-term debt		79,375,000
Subsequent Event \| SW Acquisition
Subsequent Event [Line Items]
Acquisition, purchase price			$ 30,665,000
Subsequent Event \| Breckenridge Acquisition
Subsequent Event [Line Items]
Acquisition, purchase price		$ 102,900,000
Subsequent Event \| Alpine Acquisition
Subsequent Event [Line Items]
Acquisition, purchase price	$ 5,133,000
Class 2 Common Stock \| Subsequent Event \| SW Acquisition
Subsequent Event [Line Items]
Acquisition, number of shares issued	82,224		843,687
Acquisition, fair value of shares issued	$ 776,000		$ 8,741,000
Class 2 Common Stock \| Subsequent Event \| Breckenridge Acquisition
Subsequent Event [Line Items]
Acquisition, number of shares issued		11,245,511
Class 2 Common Stock \| Subsequent Event \| Alpine Acquisition
Subsequent Event [Line Items]
Acquisition, number of shares issued	366,308
Acquisition, fair value of shares issued	$ 3,000,000